Page last updated: 2024-08-25

rosiglitazone and Insulin Resistance

rosiglitazone has been researched along with Insulin Resistance in 524 studies

Research

Studies (524)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (1.91)	18.2507
2000's	326 (62.21)	29.6817
2010's	177 (33.78)	24.3611
2020's	11 (2.10)	2.80

Authors

Authors	Studies
Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK	1
Berger, GD; Berger, J; Doebber, T; Han, W; MacNaul, K; Moller, DE; Mosley, R; Sahoo, SP; Santini, C; Tolman, RL; Wu, M	1
Avery, MA; Benson, SC; Chittiboyina, AG; Desai, PV; Ho, CI; Kurtz, TW; Mizuno, CS; Patny, A; Pershadsingh, HA; Venkatraman, MS	1
Amatruda, J; Bullock, W; Burns, M; Cantin, LD; Chuang, CY; Claus, T; Dai, M; Dela Cruz, F; Dickson, D; Ehrgott, FJ; Fan, D; Heald, S; Hentemann, M; Iwuagwu, CI; Johnson, JS; Kumarasinghe, E; Ladner, D; Lavoie, R; Liang, S; Livingston, JN; Lowe, D; Ma, X; Magnuson, S; Mannelly, G; Mugge, I; Ogutu, H; Pleasic-Williams, S; Schoenleber, RW; Shapiro, J; Shelekhin, T; Sweet, L; Town, C; Tsutsumi, M; Wickens, P; Zhang, C; Zhao, Q	1
Cui, X; He, Y; Tang, L; Wang, J; Wu, H; Zhang, J; Zhu, G	1
Abad, MC; Askari, HB; De, D; Gaul, MD; Geisler, JG; Kasturi, J; Kemmerer, M; Kim, AJ; Lenhard, JM; Lin, L; Liu, J; O'Neill, JC; Patch, RJ; Player, MR; Rentzeperis, D; Searle, LL; Zhu, X	1
Altieri, F; Azzariti, A; Cervoni, L; Crestani, M; Di Giovanni, C; Fracchiolla, G; Gilardi, F; Giudici, M; Guerrini, U; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Montanari, R; Paradiso, A; Piemontese, L; Pochetti, G; Porcelli, L; Simone, GM; Tortorella, P	1
Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C	1
Aramaki, H; Beckmann, H; Biermann, D; Chen, JL; Cushing, TD; Flygare, J; Frankmoelle, W; Furukawa, N; Hagiwara, A; Houze, JB; Iida, T; Jaen, J; Kearney, P; Kitao, Y; Learned, MR; Li, Y; Lindstrom, M; Liu, J; McGee, LR; Miao, S; Motani, A; Nakamura, M; Nishiu, J; Rubenstein, SM; Shinkai, H; Taygerly, JP; Thoolen, M; Timmermans, PB; Walker, N; Wang, Z; Weiszmann, J; Ye, G	1
Chen, Z; Hu, C; Lu, D; Tang, YB; Tian, JY; Wu, L; Xiao, Z; Yang, Y; Ye, F; Zhang, ZY	1
Kanojiya, S; Maurya, R; Mishra, A; Pandey, J; Patel, OP; Raju, KS; Saini, D; Shukla, SK; Srivastava, AK; Srivastava, MN; Tamrakar, AK; Taneja, I; Wahajuddin, M; Yadav, PP	1
Bao, L; Chen, B; Han, J; Liu, H; Luo, H; Ma, K; Ren, J; Wang, K; Zhang, J	1
Cerchia, C; Colantuoni, V; Convertini, P; Dal Piaz, F; Iacobazzi, V; Infantino, V; Laghezza, A; Lavecchia, A; Loiodice, F; Lupo, A; Piemontese, L; Sblano, S; Tortorella, P; Ziccardi, P	1
Cao, S; Chen, Q; Cui, M; Jiang, H; Kang, N; Li, D; Qiu, F; Wang, T; Wang, Z; Zhou, J	1
Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB	1
Brunetti, L; Cerchia, C; Genovese, M; Gilardi, F; Laghezza, A; Lavecchia, A; Leuci, R; Loiodice, F; Paoli, P; Piemontese, L; Santi, A; Sblano, S; Thomas, A; Tortorella, P	1
Chen, C; Chen, X; Huang, J; Jose, PA; Ni, Y; Ren, H; Shao, M; Su, Q; Wang, Y; Yan, H; Yang, J; Zhang, F; Zhong, J	1
Achenbach, A; Amri, EZ; Atkinson, DL; Boudina, S; Bowman, F; Buffolo, M; Chaurasia, B; Ferhat, M; Franklin, S; Holland, WL; Ilkun, O; Makaju, A; Pires, KM	1
Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA	1
Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q	1
Chen, L; Hua, X; Liu, G; Song, W; Sun, P; Wang, Y; Wu, J; Xiong, J; Yu, W	1
Lebovitz, HE	1
Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM	1
Bajaj, M; Coarfa, C; Cox, AR; Felix, JB; Hamilton, MP; Hartig, SM; Masschelin, P; Putluri, N; Putluri, V; Rajapakshe, K; Saha, PK	1
Mourad, AAE; Mourad, MAE	1
Jacobs, C; Kumari, M; Lyubetskaya, A; Roh, HC; Rosen, ED; Taleb, S; Tenen, D; Tsai, LT	1
Gong, L; Jin, H; Li, Y; Quan, Y; Tang, Q; Yang, J; Zou, Z	1
D'Souza, K; Kane, DA; Kershaw, EE; Kienesberger, PC; Pulinilkunnil, T; Touaibia, M	1
Ding, S; Wang, X; Wen, F; Xu, Z; Yang, J; Zhuge, Q; Zhuge, W	1
Chesson, BC; Cortez, I; Denner, L; Dineley, KT; Folorunso, O; Franklin, WF; Haidacher, SJ; Hsu, WJ; Laezza, F; Lichti, CF; Nenov, MN; Rudra, JS; Sadygov, RG; Singh, AK; Taglialatela, G; Wildburger, NC	1
Colca, JR; Cole, SL; Finck, BN; Hodges, WT; Kletzien, RF; McCommis, KS; McDonald, WG; Oonthonpan, L; Schweitzer, GG; Taylor, EB; Vigueira, PA	1
den Hartigh, LJ; Goodspeed, L; Houston, B; Turk, KE; Wang, S	1
Choe, C; Ciaraldi, TP; Farr, O; Henry, RR; Hwang, WM; Kang, MC; Kim, SS; Kim, YB; Lim, DM; Mantzoros, C; Park, KS; Seo, JA	1
Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z	1
Jeong, SY; Kang, S; Kim, DS; Park, S	1
Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E	1
Liu, J; Wang, LN	1
Choi, ET; Hu, W; Nanayakkara, GK; Shao, Y; Wang, H; Xu, K; Yang, F; Yang, WY; Yang, X	1
Bi, J; Chen, X; Mao, J; Sun, K; Tang, H; Wu, H	1
Arsenault, BJ; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Laberge, AS; Piché, ME; Poirier, P	1
Arslanian, SA; Braffett, BH; Caprio, S; Geffner, ME; Kelsey, MM; Levitsky, LL; McKay, SV; Shah, R; Sprague, JE	1
Mahboob, T; Tabassum, A; Yasmeen, K; Zaidi, SNF	1
Chen, J; Deng, S; Essandoh, K; Fan, GC; Gu, H; Holland, J; Huang, K; Jegga, AG; Li, Y; Liu, T; McNamara, RK; Mu, X; Nakamura, T; Peng, J; Peng, T; Perez-Tilve, D; Wang, B; Wang, X; Yates, E	1
Andrade, ML; Blanchard, PG; Caron, A; Castro, É; Côté, M; Deshaies, Y; Dias, FA; Festuccia, WT; Gélinas, Y; Guerra-Sá, R; Moreira, RJ; Oliveira, TE; Ortiz-Silva, M; Peixoto, AS	1
Bakhtiyari, S; Haghani, K; Khatami, M; Rashidinejad, A; Zaherara, M	1
Craig, A; Issberner, J; Parvez, F	1
Albu, J; Chiu, YL; Donovan, D; Engelson, E; Ernst, J; Ginsberg, HN; Glesby, MJ; Ham, K; He, Q; Kotler, DP; Lesser, M; Muthukrishnan, V	1
Lin, CH; Shih, CC; Shlau, MT; Wu, JB	1
Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C	1
Cetinkalp, S; Ertek, S	1
Bravard, A; Disse, E; Laville, M; Rieusset, J; Tchernof, A; Veilleux, A; Vidal, H	1
Choi, JM; Jin, SM; Kim, JH; Kim, KW; Lee, S; Oh, BJ; Park, CY; Park, SW; Yang, SJ	1
Burcelin, R; Campbell, M; Camps, M; Decaunes, P; Domingo, P; Escoté, X; Fernández-Real, JM; Frühbeck, G; Galitzky, J; Giralt, M; Kolditz, CI; Langin, D; Laville, M; Luche, E; Michalski, MC; Mingrone, G; Moreno-Navarrete, JM; Ortega, F; Pardo, G; Ricart, W; Rodriguez-Hermosa, JI; Sabater, M; Salvador, J; Serino, M; Vendrell, J; Vidal, H; Vidal-Puig, A; Viguerie, N; Villarroya, F; Waget, A; Xifra, G; Zorzano, A	1
Burcelin, R; Fernández-Real, JM; Frühbeck, G; Luche, E; Mayas, D; Mingrone, G; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodriguez-Hermosa, JI; Serino, M; Tinahones, FJ	1
Li, L; Li, Y; Lin, H; Liu, J; Liu, X; Niu, Y; Wang, F; Yan, J	1
Huang, L; Weng, C; Xing, X; Yang, Y; Yuan, H	1
Anthony, J; Bhumra, SK; Deka, N; Kelkar, A; Marita, AR; Mutt, S; Mutt, SJ; Ranjith, V; Sharma, S; Sivaramakrishnan, H; Wilankar, C	1
Chang, Y; Hu, S; Li, Z; Wang, J; Wang, Y; Xue, C	1
Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A	1
Chen, S; Cheng, Q; Gao, R; Li, Q; Liu, L; Luo, M; Luo, T; Lv, Q; Xia, W; Yang, S; Zhang, W; Zhou, H	1
Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR	1
Fan, N; Hou, Y; Liu, R; Peng, L; Peng, Y; Shen, W; Sun, H; Wang, Y; Xia, Z; Zhang, L	1
Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A	1
Hao, M; Hu, YR; Kuang, HY; Xiao, YC; Zheng, JX	1
Narasimhan, S; Weinstock, RS	1
Chevalier, S; Farsijani, S	1
Gao, R; Guo, T; Hu, X; Li, J; Liu, Z; Mei, H; Ming, Y; Song, Y; Wang, B; Wu, C; Xiao, L; Xiao, X; Zhang, Y	1
You, S; Zhou, X	1
Diano, S; Horvath, TL; Jeong, JK; Long, L; Toda, C	1
Li, YX; Sun, Q; Zeng, JB; Zhang, Y	1
Meierhofer, D; Sauer, S; Weidner, C	1
Armoni, M; Harel, C; Karnieli, E	1
Bakhtiyari, S; Gerayesh-Nejad, S; Meshkani, R; Sadeghi, A; Taheripak, G; Zarghooni, M	1
Jang, MK; Jung, MH	1
Abdel-Rahman, E; Ahuja, M; Amin, AT; Amin, RH; Bagasrawala, I; Dhanasekaran, M; Kariharan, T; Nanayakkara, G; Parameshwaran, K; Suppiramaniam, V	1
Albu, JB; Engelson, ES; Glesby, MJ; He, Q; Kotler, DP	1
Barakat, W; El-Maraghy, N; Reda, E; Saleh, S	1
Chen, Y; Han, H; Liu, B; Wang, J; Xu, F; Xue, M; Yuan, Q	1
Shieh, KR; Tseng, HL; Yang, SC; Yang, SH	1
Geng, B; He, J; Jiang, H; Kuang, J; Liu, Q; Mo, L; Xu, C; Xu, G	1
Babakhani, A; Bakhtiyari, S; Haghani, K; Karimfar, MH	1
Amato, AA; Arumanayagam, AS; Cvoro, A; de Assis Rocha Neves, F; de Lima, Mdo C; Filgueira, CS; Milton, FA; Pitta, IR; Sieglaff, DH; Webb, P	1
Abadie, KV; Bader, DA; Bajaj, M; Chan, L; Hamilton, MP; Hartig, SM; Long, W; Mancini, MA; McGuire, SE; Moore, DD; Motamed, M; Mueller, M; Trauner, M; Wagner, M; York, B	1
Hu, S; Shi, D; Wang, J; Wang, Y; Xue, C; Zhao, Y	1
Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Sripetchwandee, J	1
Han, JS; Park, MH	1
Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A	1
Chao, CY; Hsu, CC; Kuo, YH; Li, PY; Tang, FY; Yin, MC	1
Cui, WW; Jin, X; Zhang, HX	1
Bhatnagar, A; Conklin, DJ; Haberzettl, P; McCracken, JP	1
Pugalendi, KV; Radhiga, T; Sundaresan, A	1
Franczyk, MP; Imai, S; Kelly, SC; Moseley, AC; Qi, N; Stromsdorfer, KL; Yamaguchi, S; Yoon, MJ; Yoshino, J	1
Balaz, M; Modica, S; Neubauer, H; Profant, M; Simon, E; Stefanicka, P; Straub, LG; Sun, W; Ukropcova, B; Ukropec, J; Varga, L; Wolfrum, C	1
Chen, Y; Daurio, NA; Eiermann, GJ; Erion, MD; Fancourt, C; Herath, K; Hwa, J; Kelley, DE; Metzger, D; Miller, C; Nawrocki, AR; Petrov, A; Previs, SF; Roddy, TP; Satapati, S; Shen, X; Slipetz, D; Wang, SP; Yao, Z; Yin, W; Zhou, D	1
Andres, A; Badger, TM; Blackburn, ML; Chen, JR; Frye, RE; Lazarenko, OP; Rose, S; Shankar, K	1
Aslanidis, C; Buechler, C; Eisinger, K; Haberl, EM; Krautbauer, S; Neumann, M; Pohl, R; Rein-Fischboeck, L; Schacherer, D; Weiss, TS; Zimny, S	1
Colle, R; Corruble, E; de Larminat, D; Fève, B; Hardy, P; Hozer, F; Rotenberg, S; Verstuyft, C	1
Brunt, JJ; Cai, EP; Krishnamurthy, M; Luk, CT; Schroer, SA; Shi, SY; Sivasubramaniyam, T; Winer, DA; Woo, M	1
Burkart, A; Chawla, A; Chouinard, M; Corvera, S; Czech, MP; Konda, S; Lin, C; Nicoloro, SM; Perugini, RA; Puri, V; Ranjit, S; Straubhaar, J	1
Cho, YM; Choi, HH; Chung, SS; Kim, JH; Lee, HK; Lee, KW; Park, HS; Park, KS	1
Berry, EA; de Jong, SA; Manning, PJ; Sutherland, WH; Walker, RJ; Williams, SM	1
Banz, WJ; Bollaert, M; Chickris, N; Higginbotham, A; Iqbal, MJ; Rockway, S	1
Hamilton, JK; Hanley, AJ; Retnakaran, R; Shen, S; Vuksan, V; Zinman, B	1
Abbasi, F; Chen, YD; Farin, HM; Lamendola, C; Reaven, GM	1
Hong, SM; Kim, YS; Kwon, DY; Park, S	1
Huang, W; Huang, XZ; Yu, RM; Zhu, HL	1
Gaikwad, AB; Pathan, AR; Ramarao, P; Viswanad, B	1
Janez, A; Jensterle, M; Keber, I; Kocjan, T; Pfeifer, M; Prezelj, J; Sebestjen, M	1
Derosa, G; Salvadeo, SA	1
Felson, S; Fisher, E; Schwartzbard, A; Zinn, A	1
Chen, XZ; Li, L; Liu, WP; Niu, YF; Tian, CF; Xie, MJ; Zuo, YQ	1
Chen, HS; Juan, CC; Lin, HD; Wu, TE	1
Mitkov, M; Pekhlivanov, B	1
Hong, TP; Liu, GQ; Liu, Z; Wang, HN; Wang, YR; Wei, XL; Wu, PX	1
Brunani, A; Castagna, G; Gondoni, LA; Graci, S; Liuzzi, A; Titon, A; Viberti, GC	1
Araujo de Baptista, E; Baptista, T; Beaulieu, S; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E	1
Borba, CP; Boxill, R; Cather, C; Copeland, PM; Eden Evins, A; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B	1
Arroyo, V; Clària, J; Dong, B; Ferré, N; González-Périz, A; Gronert, K; Horrillo, R; López-Parra, M; Martínez-Clemente, M; Morán-Salvador, E; Titos, E	1
Abbasi, F; Lima, NK; Reaven, GM	1
Berthelot, P; Caignard, DH; Caüzac, M; Clément, L; Cruciani-Guglielmacci, C; Dacquet, C; Kassis, N; Ktorza, A; Lebègue, N; Magnan, C; Ouali, F; Pégorier, JP; Renard, P; Sohn, KA	1
Ahn, CW; Cha, BS; Kim, HJ; Kim, SK; Lee, HC; Lee, YJ; Ma, ZA; Shim, WS; Zhao, Z	1
Rechler, MM; Zappalà, G	1
Bai, X; Chen, J; Chen, X; Fang, J; Liu, Y; Tian, L; Zhou, J; Zhou, Q	1
Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S	1
Hui, X; Kraegen, EW; Lam, KS; Li, Y; Wang, Y; Wu, D; Xu, A; Zhang, J; Zhu, W	1
Annicotte, JS; Chavey, C; Clapé, C; Fajas, L; Guma, A; Hotamisligil, GS; Iankova, I; Jardin-Watelet, B; Lagarrigue, S; Langin, D; Lazennec, G; Mataki, C; Renard, E; Sanches, R; Schmidt, J; Stich, V; Strieter, R; Teyssier, J; Tuthill, A; Vidal-Puig, A; Vitkova, M; Yamamoto, H; Zorzano, A	1
Feng, CR; He, QJ; Lou, YJ; Wu, HS; Yang, B; Zhou, CX; Zhu, DF	1
Cai, B; Chen, L; Pan, Y; Wang, K; Wang, S; Xu, B; Yu, X; Zhou, S	1
Li, K; Li, L; Liu, H; Yang, G; Yang, M; Zong, H	1
Liou, SS; Liu, IM; Tzeng, TF	1
Asp, ML; Belury, MA; Tian, M; Wendel, AA	1
Akarca, U; Akyildiz, M; Batur, Y; Cetinkalp, S; Omer, Z; Yilmaz, C; Yilmaz, F	1
Ackermans, M; Blümer, RM; Endert, E; Reiss, P; Sauerwein, HP; Serlie, MJ; van der Valk, M	1
Ersoy, C; Guclu, M; Gul, CB; Imamoglu, S; Kiyici, S; Oral, AY; Oz Gul, O; Tuncel, E; Ulukaya, E; Yilmaz, Y	1
Hamada, Y	1
Chen, Y; Li, Y; Sun, C; Wang, Y; Wen, Y	1
Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G	1
Blüher, M; Catalán, V; Fernández-Real, JM; Frühbeck, G; Gómez-Ambrosi, J; Martínez-Barricarte, R; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodríguez de Cordoba, S; Sabater, M	1
Gupta, S; Hrishikeshvan, HJ; Sehajpal, PK	1
Depaoli, AM; Higgins, LS	1
Alevizos, M; Angelopoulou, N; Athanasiadou, Z; Iliadis, F; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Vitta, I; Vrabas, IS	1
Gao, F; Huang, C; Huang, Y; Li, R; Wang, W; Wang, X; Zhang, H	1
Boerman, OC; Meijer, P; Oyen, WJ; Rennings, AJ; Rongen, GA; Smits, P; Tack, CJ; van Uden, DJ	1
Berenguer, M; Bruce, MC; Govers, R; Le Marchand-Brustel, Y; Martinez, L	1
Agrawal, A	1
Flachs, P; Hensler, M; Jelenik, T; Kopecky, J; Kuda, O; Rossmeisl, M; Stankova, B; Tvrzicka, E	1
Limor, R; Oron, Y; Rosenthal, T; Stern, N; Younis, F; Zangen, S	1
DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C	1
Bahia, LR; Bouskela, E; Domingues, RC; Geloneze, B; Godoy-Matos, AF; Kraemer-Aguiar, LG; Tambascia, M	1
Ahn, CW; Cha, BS; Cho, M; Kim, KR; Lee, EJ; Lee, HC; Lim, SK; Nam, JS; Nam, JY; Park, JS; Yoo, JS	1
Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P	1
Aquilante, CL; Knutsen, SD; Kosmiski, LA; Rome, LC; Zineh, I	1
Fowler, MB; Gambhir, SS; Kao, DP; Quon, A; Witteles, RM; Wu, JC	1
Kenna, HA; Powers, B; Rasgon, NL; Schatzberg, AF; Williams, KE; Wroolie, T	1
Caveda, E; Rodriguez, A; Simó, R	1
Abbasi, F; Lamendola, C; Reaven, GM	1
Benomar, Y; Bouchaert, E; Casteilla, L; Dacquet, C; Dumont, J; Guédin, A; Hennuyer, N; Ktorza, A; Langlois, A; Lefebvre, B; Lefebvre, P; Pattou, F; Pénicaud, L; Staels, B	1
Brosius, FC; Duan, SZ; Foley, EL; Milstone, DS; Mortensen, RM; Usher, MG	1
Huang, Y; Tian, J; Tian, XY; Wang, N; Wong, WT; Zhang, P	1
Lee, JS; Padmanabhan, V; Veiga-Lopez, A	1
Larson, RJ; Sheth, SH	1
Chaudhuri, A; Dandona, P; Ghanim, H	1
Döbrönte, R; Drimba, L; Németh, J; Pázmány, T; Peitl, B; Sári, R; Szilvássy, Z; Varga, A	1
Almdal, T; Boushel, R; Dela, F; Hansen, CN; Haugaard, SB; Madsbad, S; Ploug, T; Prats, C; Rabøl, R	1
Blüher, M; de Waha, S; Desch, S; Eitel, I; Niebauer, J; Sareban, M; Schuler, G; Sixt, S; Sonnabend, M; Thiele, H	1
Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y	1
Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP	1
Clemenz, M; Foryst-Ludwig, A; Hartge, M; Hess, K; Kintscher, U; Marx, N; Sprang, C; Unger, T	1
Bae, MH; Chae, YN; Choi, HH; Choi, SH; Hur, Y; Kim, E; Kim, JG; Kim, MK; Lim, JI; Moon, HS; Park, CS; Park, YH; Shin, CY; Son, MH	1
Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I	1
Gao, Y; Hu, SG; Ma, HJ; Qu, DM; Song, GY; Wang, C; Wang, J	1
Dhanjil, S; Godsland, IF; Johnston, DG; Pavitt, DV; Richmond, W; Yee, MS	1
Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P	1
Chowdhury, HH; Kreft, M; Velebit, J; Zorec, R	1
Fernandes, G; Halade, GV; Lindsey, ML; Williams, PJ	1
Chang, B; Chen, L; Dong, L; Li, M; Li, XY; Lian, FM; Liu, WK; Qin, PJ; Tong, XL; Wang, J; Yu, B; Zhang, JH; Zhen, Z	1
Bao, Y; Hu, C; Jia, W; Jiang, F; Lu, J; Qin, W; Tang, S; Wang, C; Xiang, K; Yu, W; Zhang, R	1
Ahmed, AF; El-Moselhy, MA; El-Sisi, SF; Sharkawi, SS; Taye, A	1
Arslanian, S; Lee, S; Sutton-Tyrrell, K; Tfayli, H; Ulnach, JW	1
Chen, W; Liu, HY; Wang, LL; Zhang, LH; Zhou, XB	1
Deen, PM; Li, Y; Masereeuw, R; Rennings, AJ; Russel, FG; Smits, P; Tack, CJ	1
Chan, DT; Dogra, GK; Irish, AB; Watts, GF	1
Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B	1
Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ	1
Bandyopadhyay, G; Fan, W; Gayen, JR; Li, P; Lu, M; Mahata, SK; Nalbandian, S; Olefsky, JM; Sarruf, DA; Schwartz, MW; Sharma, S; Talukdar, S; Webster, NJ	1
Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY	1
Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N	1
Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B	1
Hu, W; Qiao, J	1
Andres, J; Assmann, A; Biedasek, K; Bobbert, T; Diederich, S; Graham, I; Larson, TR; Mai, K; Pfeiffer, AF; Spranger, J	1
Minhu, C; Yao, J; Zhi, M	1
Mohsen, IA	1
Kamal, MA; Qu, X; Seale, JP; Sun, LQ; Tan, Y; Wang, X	1
Fantus, IG; Grynpas, MD; Renlund, R; Sardone, LD; Willett, TL	1
Chabowski, A; Górski, J; Nawrocki, A; Zendzian-Piotrowska, M	1
Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N	1
Abbasi, A; Lee, WN; Rehan, VK; Sakurai, R; Torday, JS; Truong, NC	1
Asp, ML; Belury, MA; Kliewer, KL; Tian, M	1
Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Pratchayasakul, W	1
Cao, XG; Chen, XH; Gao, CL; Guo, XR; Ji, CB; Qin, R; Qin, ZY; Zhang, CM; Zhang, M; Zhao, HM; Zhao, YP; Zhu, C	1
Panadero, A; Pita, J; Rodríguez, E; Rovira, A; Soriano-Guillén, L	1
Elased, KM; Lucot, JB; Sharma, AN	1
Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M	1
Aguila, MB; Fraulob, JC; Mandarim-de-Lacerda, CA; Souza-Mello, V	1
Baracat, EC; Batista, JG; Maganhin, CC; Simões, RS; Soares, JM; Tomaz, G	1
Balguy, I; Benelli, C; Cadoudal, T; Distel, E; Durant, S; Penot, G	1
Chambers, KT; Chen, Z; Colca, JR; Finck, BN; Hall, AM; Kletzien, RF; McDonald, WG; Mitra, MS; Qi, N; Vigueira, PA	1
Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L	1
Arias, P; Astort, F; Berg, G; Cymeryng, CB; Di Gruccio, JM; Martinez Calejman, C; Mercau, ME; Pandolfi, M; Repetto, EM; Sanchez, R; Schreier, L	1
Khalaf, KI; Taegtmeyer, H	1
Feng, Y; Ruan, KF; Wang, LY; Wang, S; Wang, Y; Xu, DS	1
Li, D; Liu, JH; Wang, GL; Wang, L; Wu, LN; Zhu, DZ	1
Jang, JE; Jeon, MJ; Kim, EH; Kim, HS; Kim, M; Ko, MS; Koh, EH; Lee, CH; Lee, KU; Leem, J; Park, HS; Park, IS; Yoo, HJ	1
Brooks, VL; McCully, BH; Zhao, D	1
Chen, YE; Guo, X; Halim, V; Huo, Y; Li, H; Sturino, JM; Thomas, LN; Woo, SL; Wu, C; Xu, H	1
Davaa, E; Park, JS	1
Chen, SG; Cheng, XY; He, JW; Li, H; Lu, ML; Qu, S; Sheng, CJ; Wang, C; Wang, KS; Yu, YC	1
Bhandari, S; Semple, DJ; Seymour, AM	1
Du, Q; Fan, B; Wang, YJ; Wu, B; Yang, S; Zhao, YY	1
Bland, JS; Darland, G; Havekes, LM; Konda, V; Romijn, JA; Tripp, ML; van den Berg, SA; van Diepen, JA; van Dijk, KW; Voshol, PJ; Vroegrijk, IO	1
Ametov, AS; Goncharenko, ON; Isakova, MR	1
Aziz, AR; Deliard, S; Grant, SF; Zhao, J	1
Hodnett, PA; Maher, MM; McLaughlin, PD; O'Halloran, D; Ryan, J	1
Cai, Q; Gao, Z; Liang, G; Liu, B; Liu, D; Xu, G	1
Ahbap, E; Basturk, T; Borlu, F; Koc, Y; Sakaci, T; Ulas, T; Unsal, A	1
Jyothi Kumari, P; Lakshmi, BS; Sangeetha, KN; Shilpa, K	1
Beydoun, H; Beydoun, M; Kancherla, V; Stadtmauer, L	1
Arévalo, MI; Barberà, A; Caelles, C; Gomis, R; Lanuza-Masdeu, J; Vila, C	1
Li, M; Lin, Y; Ma, Y; Zheng, Z	1
Häring, HU; Stumvoll, M	1
Yamanouchi, T	1
Oka, Y	1
Brathwaite, CE; Brebbia, JS; Fuhrer, J; Gelato, MC; McNurlan, MA; Mynarcik, DC; Quick, JL; Steigbigel, RT; Wax, MR	1
Desvergne, B; Escher, P; Michalik, L; Niesor, E; Rieusset, J; Touri, F; Wahli, W	1
Craft, S; Watson, GS	1
Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM	1
Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M	1
Bekins, SA; Raji, A; Seely, EW; Simonson, DC; Williams, GH	1
Dey, CS; Kumar, N	1
Kazdová, L; Kren, V; Krenová, D; Seda, O	1
Cleasby, ME; Livingstone, DE; Nyirenda, MJ; Seckl, JR; Walker, BR	1
Cooney, GJ; Ellis, B; Iglesias, MA; Jensen, PB; Kraegen, EW; Larsen, PJ; Sørensen, RV; Wassermann, K; Watson, DG; Wood, L; Ye, JM	1
Shaarawy, M; Shobokshi, A	1
Brewer, B; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Lambert, G; Matsusue, K; Reitman, ML; Ward, JM; Yim, SH	1
Bryer-Ash, M; Ghazeeri, G; Haas, D; Ke, RW; Kutteh, WH	1
Plosker, SM	1
Viberti, GC	1
Bacon, BR; Brunt, EM; Hampton, K; Neuschwander-Tetri, BA; Sponseller, CA; Wehmeier, KR	1
Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL	1
Fischer, S; Hanefeld, M	1
Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF	1
Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM	1
Chao, L; Chen, Y; Choi, H; Fillmore, JJ; Gavrilova, O; Haluzik, M; Higashimori, T; Kim, HJ; Kim, JK; Qu, X; Reitman, ML; Shulman, GI; Yu, C	1
Cutson, JJ; Dietz, KR; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Johnson, L; Matsusue, K; Nicol, CJ; Reitman, ML; Vinson, C	1
Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D	1
Haffner, SM	1
Bandyopadhyay, G; Beeson, M; Dizon, M; Farese, RV; Gomez-Daspet, J; Grebenev, D; Kanoh, Y; Miura, A; Powe, J; Sajan, MP; Standaert, ML	1
Havekes, LM; Mensink, RP; Muurling, M; Pijl, H; Romijn, JA; Voshol, PJ	1
Cawthorne, MA; Converset, V; Heller, M; Hochstrasser, DF; Nolan, A; Sanchez, JC; Schmid, G; Sennitt, MV; Wang, S	1
Häkkinen, AM; Halavaara, J; Järvinen, A; Ristola, M; Seppälä-Lindroos, A; Sutinen, J; Vehkavaara, S; Westerbacka, J; Yki-Järvinen, H	1
Donohoe, M; Ellard, S; Hattersley, AT; Owen, KR	1
Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR	2
Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z	1
Abrahám, C; Benko, I; Djazayeri, K; Szilvássy, Z; Zsuga, J	1
Hsu, YJ; Hung, YJ; Kuo, SW; Lin, SH; Lin, YF	1
Chilton, RJ; Stolar, MW	1
Henry, RR	1
Auclair, M; Bastard, JP; Capeau, J; Caron, M; Lagathu, C; Maachi, M	1
Evans, M; Rees, A; Roberts, AW; Thomas, A	1
Cowan, D; Kaski, JC; Sidhu, JS	1
Barak, Y; Evans, RM; He, W; Hevener, A; Le, J; Liao, D; Nelson, M; Olefsky, JM; Olson, P; Ong, E	1
Currier, J	1
Barnes, GT; Chen, H; Chou, CJ; Nichols, A; Ross, JS; Sole, J; Tan, G; Tartaglia, LA; Xu, H; Yang, D; Yang, Q	1
Lokhandwala, M; Marwaha, A; Trivedi, M	1
Asnani, S; DeSouza, C; Fonseca, V; Gilling, L; Suwattee, P	1
Cohen, SE; Kahn, CR; Michael, MD; Tseng, YH	1
Fischer, S; Fuecker, K; Gross, P; Hanefeld, M; Passauer, J; Pistrosch, F	1
Ehrenborg, E; Fisher, RM; Funahashi, T; Hamsten, A; Kannisto, K; Korsheninnikova, E; Matsuzawa, Y; Nyman, T; Sutinen, J; Vidal, H; Virkamäki, A; Yki-Järvinen, H	1
Petersen, KU	1
Accili, D; Carnemolla, R; Han, S; Liang, CP; Okamoto, H; Tabas, I; Tall, AR	1
Cline, GW; Davies, PJ; Leibowitz, MD; Shen, Q; Shulman, GI	1
Kaposzta, Z; Kaski, JC; Markus, HS; Sidhu, JS	1
Bains, RK; Fairhall, KM; Flavell, DM; Le Tissier, P; Robinson, IC; Strom, M; Wells, SE	1
Belli, SH; Graffigna, MN; Levalle, OA; Oneto, A; Otero, P; Schurman, L	1
Bode, C; Ernst, S; Leugers, A; Lohrmann, J; Nordt, TK; Sobel, BE; Zirlik, A	1
Béréziat, V; Burnol, AF; Capitaine, N; Cariou, B; Girard, J; Kergoat, M; Laville, M; Le Marcis, V; Vega, N; Vidal, H	1
Agrawal, A; Bennett, SM; Elasha, H; Heise, M; Jones, NP; Walker, M; Wilding, JP	1
Singh, N	1
Gao, HY; Jia, P; Zhang, CL; Zhao, ZG	1
Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH	1
Adeli, K; Leung, N; Lewis, GF; Naples, M; Szeto, L; Uffelman, K	1
Grinspoon, S; Hadigan, C; Havers, F; Sax, PE; Thomas, A; Yawetz, S	1
Le Feuvre, C	2
Durbin, RJ	1
Al-Haddad, W; Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Hofmeyer, D; Mohanty, P; Syed, T; Tripathy, D	1
Cowan, D; Kaski, JC; Sidhu, JS; Tooze, JA	1
Cleasby, ME; Cooney, GJ; Dzamko, N; Furler, SM; Hegarty, BD; Kraegen, EW; Ye, JM	1
Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C	1
Häkkinen, AM; Korsheninnikova, E; Mäkimattila, S; Nyman, T; Tiikkainen, M; Yki-Järvinen, H	1
Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AN; Tziolas, IM; Yovos, JG; Zebekakis, PE	1
de Alvaro, C; Hernandez, R; Lorenzo, M; Teruel, T	1
Dufour, JF; Oneta, CM	1
Baillargeon, JP; Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE	1
Nagamani, M; Sepilian, V	1
Adeli, K; Haidari, M; Lewis, GF; Naples, M; Szeto, L; Uffelman, K	1
Adeli, K; Albers, A; Brunzell, JD; Lewis, GF; Murdoch, S; Naples, M; Szeto, L; Uffelman, K	1
Füchtenbusch, M; Löbner, K	1
Bullock, M; Gaillard, T; Kaplow, J; Osei, K; Schuster, D	1
Flynn, ER; Pedersen, WA	1
Asberg, A; Hartmann, A; Hjelmesaeth, J; Jenssen, T; Simonsen, C; Voytovich, MH	1
Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB	1
Fan, SC; He, CT; Hsieh, CH; Hung, YJ; Kuo, SW; Lee, CH; Lee, JT; Pei, D; Sheu, WH; Wu, LY	1
Liu, Y; Lv, L	1
Brunani, A; Caumo, A; Graci, S; Liuzzi, A; Margarini, C; Viberti, GC	1
Bao, W; Cui, J; Gu, JL; Jucker, BM; Ma, XL; Ohlstein, EH; Tao, L; Yue, TL	1
Hanefeld, M	1
Bouskila, M; Pajvani, UB; Scherer, PE	1
Hegele, RA	1
Chen, YY; Li, CM; Li, GW; Li, H; Liu, KL; Tang, YL; Wang, JP; Xing, XY; Yang, WY	1
Cho, YM; Jung, HS; Kim, SY; Lee, HK; Park, HJ; Park, KS; Shin, CS; Youn, BS; Yu, KY	1
Carey, D; Carr, A; Cooper, DA; Emery, S; Feneley, MP; Kovacic, JC; Mallon, PW; Martin, A; Wand, H	1
Hitoglou-Makedou, AD; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AA; Yovos, JG	1
Carvalheira, JB; Carvalho-Filho, MA; Curi, R; de Oliveira, MG; Hirabara, SM; Saad, MJ; Seabra, AB; Ueno, M; Velloso, LA	1
Lokhandwala, MF; Trivedi, M	1
Feng, SD; Hu, B; Ling, HY; Liu, XQ; Wang, BX; Zhou, SH	1
Ciardullo, AV	1
Ergün, I; Keven, K	1
Campbell, IW	1
Schumm-Draeger, PM	1
Fischer, S; Gross, P; Herbrig, K; Oelschlaegel, U; Passauer, J; Pistrosch, F; Richter, S	1
James, AP; Mamo, JC; Watts, GF	1
Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Ravishankar, S; Sanalkumar, N; Tripathy, D	1
Moreno Sánchez, D	1
Cantürk, Z; Cetinarslan, B; Komsuoglu, B; Sahin, T; Tarkun, I; Türemen, E	1
Ouyang, JP; Wang, SS; Wen, CY; Wu, K; Wu, Y; Xia, ZY	1
Graham, TE; Kahn, BB; Kotani, K; Mody, N; Peroni, OD; Preitner, F; Quadro, L; Yang, Q; Zabolotny, JM	1
Hirosumi, J; Ita, M; Kawamura, I; Mabuchi, M; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S; Yamamoto, T	1
Abbasi, F; Chu, JW; Kim, SH; Lamendola, C; McLaughlin, TL; Polonsky, KS; Reaven, GM	1
Chen, HL; Lei, MX; Sun, ZX; Wu, J	1
Chen, ZP; Febbraio, MA; Hashem, M; Hawley, JA; Kemp, BE; Lessard, SJ; Reid, JJ; Watt, MJ	1
Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M	1
Airaksinen, KE; Ball, E; Borra, R; Härkönen, R; Iozzo, P; Knuuti, J; Lautamäki, R; Luotolahti, M; Nuutila, P; Seppänen, M; Stewart, M; Toikka, J	1
Dazzi, D; Hassan, H; Mangieri, T; Negro, R; Pezzarossa, A	1
Bujko, J; Dzieniszewski, J; Nowicka, G; Tacikowski, T; Walewska-Zielecka, B	1
Chen, HL; Liao, L; Wu, J	1
Abbasi, F; Basina, M; Cataldo, NA; Fechner, PY; Giudice, LC; McLaughlin, TL; Reaven, GM	1
Chow, KM; Lam, CW; Leung, CB; Li, PK; Szeto, CC; Wong, TY	1
Ferrannini, E; Hällsten, K; Iozzo, P; Järvisalo, MJ; Lönnqvist, F; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, AP; Virtanen, KA	1
Liu, XL; Pan, L; Wang, N; Wang, X; Xiao, JZ; Yang, WY; Zhao, WH	1
Déchêne, F; Dodin, S; Forest, JC; Lemay, A; Turcot, L	1
Janez, A; Karner, P; Maticic, M; Sharma, PM; Tomazic, J; Vidmar, L	1
Os, I	1
Asthana, S; Baker, LD; Cholerton, BA; Cook, DG; Craft, S; Fishel, MA; Green, PS; Kahn, SE; Keeling, ML; Kulstad, JJ; Plymate, SR; Reger, MA; Watson, GS	1
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S	1
Abbasi, F; Chu, JW; Lamendola, C; McLaughlin, T; Reaven, GM; Tsao, PS	1
Hada, Y; Ito, Y; Kadowaki, T; Maki, T; Takekawa, S; Tsuchida, A; Yamauchi, T	1
Bu, S; Chen, XP; Wang, N; Wang, X; Xiao, JZ; Yang, WY; Zhao, WH	1
Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K	1
Abbasi, F; Chang, SA; Chu, JW; Ciaraldi, TP; Lamendola, C; McLaughlin, T; Reaven, GM; Reaven, PD	1
Bloedon, LT; Iqbal, N; Kochar, A; Rader, DJ; Samaha, FF; Szapary, PO; Williams, MM; Wolfe, ML	1
Mitkov, M; Pehlivanov, B; Terzieva, D	1
Dirani, RG; Freed, MI; Goldstein, BJ; Heise, MA; Kravitz, B; O'neill, MC; Porter, LE; Rosenstock, J; Vinik, AI	1
Blaak, EE; Hesselink, MK; Mensink, M; Moonen-Kornips, E; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP	1
Adomaityte, J; Qayyum, R	1
Albiger, N; Arvat, E; Cavagnini, F; Giordano, R; Leao, AA; Mantero, F; Martin, M; Pecori Giraldi, F; Picu, A; Scaroni, C	1
Arikan, E; Demir, M; Fareed, J; Guldiken, S; Kara, M; Tugrul, A; Turgut, B; Vural, O	1
Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M	1
Rennings, AJ; Smits, P; Stewart, MW; Tack, CJ	1
Orchard, TJ	1
Fan, SC; He, CT; Hsieh, CH; Hsing Lee, C; Hung, YJ; Kuo, SW; Lin, SH; Pei, D; Sheu, WH	1
Das, S; Maji, D; Roy, RU	1
Houstis, N; Lander, ES; Rosen, ED	1
Alonso, M; Vidal, A	1
Cai, ZF; Guo, ZR; Li, PP; Liu, Q; Shen, ZF	1
Aramori, I; Fujimura, T; Kimura, C; Mutoh, S; Oe, T; Sakuma, H; Takata, Y	1
Feldt, T; Fritzen, R; Goebels, K; Häussinger, D; Kambergs, J; Kappert, G; Kroidl, A; Oette, M; Vogt, C; Wettstein, M	1
Artwohl, M; Baumgartner-Parzer, SM; Haider, DG; Mittermayer, F; Prager, G; Roden, M; Schaller, G; Wolzt, M	1
Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ	1
Erbe, DV; Gartrell, K; Kirincich, SJ; Perreault, M; Suri, V; Tobin, JF; Wang, S; Will, S; Zhang, YL	1
Du, J; Hu, J; Hu, Z; Mitch, WE; Wang, X	1
Parson, H; Ullal, J; Vinik, A	1
Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ	1
Aljada, A; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Viswanathan, P	1
Bandyopadhyay, GK; Ofrecio, J; Olefsky, JM; Yu, JG	1
Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R	1
Scherbaum, WA	1
Allen, T; Bell, A; Clemens, LE; Gregoire, F; Gustafson, TA; Moodie, SA; Muscat, GE; Smith, A; Zhang, F	1
Németh, J; Pankucsi, C; Peitl, B; Szilvássy, Z	1
Cobitz, AR; Goldstein, BJ; Waterhouse, BR; Weissman, PN; Wooddell, MJ	1
Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J	1
Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J	1
Chow, WS; Hoo, RL; Kraegen, EW; Lam, KS; Sweeney, G; Tso, AW; Wang, Y; Wat, NM; Xu, A; Xu, JY; Zhang, J	1
Bošanská, L; Doležalová, R; Haluzík, M; Haluzík, MM; Kasalová, Z; Lacinová, Z; Stulc, T	1
Franck, N; Kjølhede, P; Nystrom, FH; Paulsson, JF; Sauma, L; Söderström, M; Strålfors, P; Westermark, GT	1
Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B	1
Marasciulo, FL; Montagnani, M; Potenza, MA; Quon, MJ; Tarquinio, M	1
Brunzell, JD; Chen, H; Cobitz, A; Marcovina, SM; Murdoch, SJ; Parikh, SJ; Yu, D	1
Gaillard, T; Osei, K; Schuster, D	1
Hu, FB; van Dam, RM	1
Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M	1
Haider, DG; Ludvik, B; Luger, A; Mittermayer, F; Müller, M; Nowotny, P; Rieger, A; Schindler, K; Wolzt, M	1
Kesäniemi, YA; Kunnari, A; Majuri, A; Morin-Papunen, L; Rautio, K; Ruokonen, A; Santaniemi, M; Tapanainen, JS; Ukkola, O; Vartiainen, J	1
Fövényi, J	1
Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A	1
Hesselink, MK; Mensink, M; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP	1
Bujo, H; Murakami, K; Saito, Y; Unoki, H	1
Belury, MA; Liu, LF; Purushotham, A; Wendel, AA	1
Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR	1
Hansmann, G; Perez, VA; Rabinovitch, M; Schellong, S; Sheikh, AY; Stewart, DJ; Suen, RS; Urashima, T; Wagner, RA; Wang, L	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA	1
Gaikwad, AB; Ramarao, P; Viswanad, B	1
Hirosumi, J; Kawamura, I; Kimura, C; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S	1
Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G	1
Beaser, RS; Levy, P	1
Bonen, A; Chen, ZP; Febbraio, MA; Hawley, JA; Kemp, BE; Lessard, SJ; Reeder, DW; Rivas, DA; Yaspelkis, BB	1
Kapiotis, S; Krzyzanowska, K; Mittermayer, F; Pleiner, J; Roden, M; Schaller, G; Wolzt, M	1
Andres, J; Bähr, V; Bobbert, T; Diederich, S; Mai, K; Maser-Gluth, C; Möhlig, M; Pfeiffer, AF; Spranger, J	1
Smiley, D; Umpierrez, G	1
Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ	1
Berglund, G; Donaldson, J; Hedblad, B; Nilsson, PM	1
Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B	1
Li, Y; Liu, MY; Wang, YG	1
Ecelbarger, CA; Halagappa, VK; Hu, X; Riazi, S; Tiwari, S	1
Feng, CR; He, QJ; Li, Y; Li, YY; Tang, L; Wu, HS; Yang, B; Yang, YS; Yu, JH	1
Arena, RA; Balaban, RS; Cannon, RO; Johnson, DT; Minerbi, DC; Pagel-Langenickel, I; Sack, MN; Schwartz, DR; Tripodi, DJ; Waclawiw, MA	1
Bohdanowicz-Pawlak, A; Jakubowska, J; Milewicz, A	1
Hamilton, PK; Lockhart, CJ; McVeigh, GE; Quinn, CE	1
Gao, XP; Ou, KQ; Yan, JF; Yang, GZ; Zhao, J	1
Bahtiyar, G; Sacerdote, AS; Weiss, K	1
Elasy, T; Stafford, JM	1
Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C	1
Lan, TW; Liou, SS; Liu, IM; Tzeng, TF	1
Chalasani, N; Khashab, M	1
Crum, D; Grinspoon, S; Hadigan, C; Mazza, S	1
Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S	1
Li, PP; Liu, Q; Shen, ZF; Wang, ZJ; Zou, CH	1
Fehér, J; Lengyel, G	1
Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D	1
Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M	1
Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L	1
Hong, LZ; Hsieh, PS	1
Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M	1
Emre, M; Günay, I; Kavak, S; Kavak, T; Kolcu, Z; Tetiker, T	1
Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK	1
Doggrell, SA	1
Ahn, H; Ferris, R; Gelato, MC; McNurlan, MA; Mynarcik, DC; Qurashi, S	1
Briscoe, CP; Buckingham, RE; Clapham, JC; Moore, GB; Pickavance, LC; Wilding, JP	1
Abram, SR; Carter, C; Dearman, J; Hester, RL; Xiang, L	1
Christopher, TA; Gao, F; Guo, W; Ji, Q; Li, J; Li, R; Lopez, BL; Ma, H; Ma, X; Wang, H; Zhang, H; Zhang, Q	1
Janez, A; Jensterle, M; Marc, J; Mlinar, B; Pfeifer, M; Prezelj, J	1
Cha, BS; Hwang, YC; Lee, EY; Lee, MK; Lee, WJ; Park, KS; Yoon, KH	1
Berger, JP; Chang, CH; Doebber, TW; McCann, ME; McNamara, LA; Meinke, PT; Muise, ES; Tan, Y; Thompson, JR; Wood, HB; Wu, MS	1
Corbeil, G; Hamet, P; Kazdová, L; Kren, V; Krenová, D; Oliyarnyk, O; Seda, O; Sedová, L; Tremblay, J	1
Kapoor, JR	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA	1
Chillarón, JJ; Goday, A; Pedro-Botet, J	1
Chilton, R; Sulistio, MS; Thukral, N; Zion, A	1
Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F	1
Bektas, M; Coban, S; Corapcioglu, D; Doganay, B; Emral, R; Erden, E; Idilman, R; Mizrak, D; Ozden, A; Sayki, M; Soykan, I; Uysal, AR	1
Bellmann, K; Centeno-Baez, C; Dallaire, P; Deshaies, Y; Gélinas, S; Lamontagne, J; Laplante, M; Latour, MG; Marette, A; Penfornis, P; Peyot, ML; Prentki, M; Scherer, PE; Trujillo, ME	1
Hesselink, MK; Kooi, ME; Mensink, M; Schrauwen, P; Schrauwen-Hinderling, VB; Sels, JP	1
Anderson, D; Chisholm, D; Craig, ME; Crock, P; Donaghue, KC; Stone, ML; Verge, CF; Walker, JL	1
DeFronzo, RA; Miyazaki, Y	1
Benavides, S; Romo, A	1
Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Grimaldi, A; Hartemann-Heurtier, A; Jacqueminet, S; Lacorte, JM; Podevin, P; Poynard, T; Ratziu, V; Serfaty, L	1
Kadowaki, T; Kubota, N; Takasawa, K; Terauchi, Y	1
Buckingham, RE; Cawthorne, MA; Clark, MG; Colquhoun, EQ; Eldershaw, TP; Rattigan, S	1
Chisholm, DJ; Jenkins, AB; Kennedy, CJ; Kraegen, EW; Laybutt, DR; Oakes, ND	1
Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR	1
Franciosa, MD; Greenberg, AS; Lien, P; Souza, SC; Yamamoto, MT	1
Carlberg, C; Chiesi, M; Missbach, M; Pignat, W; Spanka, C; Wiesenberg, I	1
Kern, PA; Ranganathan, S	1
Buckingham, RE; Chattington, PD; Walker, AB; Williams, G	1
Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N	1
Oberpichler-Schwenk, H	1
Kuzuya, T	1
Shimizu, N	1
Kameda, N; Oka, Y; Okuya, S	1
Horikoshi, H; Yachi, M	1
Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ	1
Bailey, CJ; Krentz, AJ; Melander, A	1
Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV	1
Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM	1
Goldstein, BJ	1
Ludvik, B	1
Filz, HP	1
Henry, RR; Mudaliar, S	1
Daubresse, JC	1
Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM	1
Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A	1
Banerji, MA; Lebovitz, HE	1
Auclair, M; Capeau, J; Caron, M; Forest, C; Glorian, M; Vigouroux, C	1
Buckingham, RE; Pickavance, LC; Wilding, JP	1
Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y	1
Jazet, IM; Meinders, AE	1
Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T	1
Birkeland, KI	1
Auwerx, J; Bac, P; Blanchard, SG; Champy, MF; Desreumaux, P; Dubuquoy, L; Gelman, L; Leesnitzer, LM; Moras, D; Picard, F; Plunket, KD; Potier, N; Renaud, JP; Rocchi, S; Vamecq, J; Zeyer, D	1
Finegood, DT; Topp, BG	1
Matthews, DR	1
Zinman, B	1
Adler, A; Bush, E; Kramer, D; Rondinone, CM; Shapiro, R	1
Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB	1
Lotz, N	1
Lund, S; Pedersen, O; Vestergaard, H	1
Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS	1
Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ	1
Adeli, K; Buckingham, R; Carpentier, A; Leung, N; Lewis, GF; Szeto, L; Taghibiglou, C; Uffelman, KD; Van Iderstine, SC	1
Scheen, AJ	1

Reviews

63 review(s) available for rosiglitazone and Insulin Resistance

Article	Year
Thiazolidinediones: the Forgotten Diabetes Medications. Current diabetes reports, 2019, 11-27, Volume: 19, Issue:12 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones	2019
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety. Burns : journal of the International Society for Burn Injuries, 2018, Volume: 44, Issue:6 Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds	2018
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane database of systematic reviews, 2017, 11-29, Volume: 11 Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin Resistance; Live Birth; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2017
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2017, 12-02, Volume: 12 Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin	2017
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. Behavioural brain research, 2019, 10-17, Volume: 372 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins	2019
Is there U-turn from insulin back to pills in diabetes? Current vascular pharmacology, 2014, Volume: 12, Issue:4 Topics: Administration, Oral; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones	2014
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2014, Volume: 39, Issue:6 Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Muscular Atrophy; Neoplasms; Nutritional Support; Proteins; Rosiglitazone; Thiazolidinediones	2014
PPAR-γ Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry, 2017, Volume: 50, Issue:2 Topics: Antidepressive Agents; Biomarkers; Blood Glucose; Depressive Disorder, Major; Fasting; Glucose Tolerance Test; Humans; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2017
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Current clinical pharmacology, 2008, Volume: 3, Issue:2 Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clinical cardiology, 2008, Volume: 31, Issue:9 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
[Relationship between insulin resistance and bone metabolism]. Clinical calcium, 2009, Volume: 19, Issue:9 Topics: Adipokines; Animals; Bone and Bones; Carbohydrate Metabolism; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. The American journal of clinical nutrition, 2010, Volume: 91, Issue:1 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Pioglitazone; PPAR gamma; Quinolines; Retinoid X Receptors; Rosiglitazone; Sulfonamides; Thiazolidinediones	2010
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Current drug safety, 2010, Jul-02, Volume: 5, Issue:3 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC infectious diseases, 2010, Jun-23, Volume: 10 Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2010
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:38 Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss	2011
After avandia: the use of antidiabetic drugs in patients with heart failure. Texas Heart Institute journal, 2012, Volume: 39, Issue:2 Topics: Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Myocardium; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2012
Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Advances in therapy, 2012, Volume: 29, Issue:9 Topics: Androgens; Blood Glucose; Body Weight; Female; Humans; Insulin; Insulin Resistance; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2012
Glitazones: clinical effects and molecular mechanisms. Annals of medicine, 2002, Volume: 34, Issue:3 Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
[Insulin sensitizer drugs--review]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2002
[Rosiglitazone (BRL-49653)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Animals; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome	2002
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS drugs, 2003, Volume: 17, Issue:1 Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Polycystic ovary syndrome and insulin resistance. Medicine and health, Rhode Island, 2003, Volume: 86, Issue:1 Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health	2003
Rosiglitazone: potential beneficial impact on cardiovascular disease. International journal of clinical practice, 2003, Volume: 57, Issue:2 Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes, obesity & metabolism, 2003, Volume: 5, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1 Topics: Age Factors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Humans; Inflammation; Insulin Resistance; Prediabetic State; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones	2003
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clinical therapeutics, 2003, Volume: 25 Suppl B Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2003
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clinical therapeutics, 2003, Volume: 25 Suppl B Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2003
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones	2003
Effects of the thiazolidinediones on cardiovascular risk factors. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2002, Volume: 2, Issue:3 Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone	2002
[Heart, diabetes and glitazones]. Annales d'endocrinologie, 2004, Volume: 65, Issue:1 Suppl Topics: Contraindications; Diabetes Mellitus, Type 2; Edema; Heart; Heart Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones	2004
[Cardiovascular effects of rosiglitazone]. Presse medicale (Paris, France : 1983), 2004, Jun-19, Volume: 33, Issue:11 Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; France; Heart Failure; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Morbidity; Primary Prevention; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents	2004
[Alcoholic and non-alcoholic steatohepatitis]. Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:8 Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss	2004
[Inflammation and diabetes]. MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36 Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones	2004
[Glucose-independent impact of the glitazones on the cardiovascular outcome]. MMW Fortschritte der Medizin, 2005, Jan-13, Volume: 147, Issue:1-2 Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Middle Aged; Obesity; Pioglitazone; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2005
Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? International journal of obesity (2005), 2005, Volume: 29 Suppl 1 Topics: Adiponectin; Animals; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Liver; Mice; Molecular Weight; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
The Clinical Significance of PPAR Gamma Agonism. Current molecular medicine, 2005, Volume: 5, Issue:3 Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Models, Chemical; Obesity; Phenotype; Pioglitazone; PPAR gamma; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides	2005
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors	2005
[Medical management of primary nonalcoholic fatty liver disease]. Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
A meta-analysis of the effect of thiazolidinediones on blood pressure. Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:1 Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones	2006
The role of PPARs in the microvascular dysfunction in diabetes. Vascular pharmacology, 2006, Volume: 45, Issue:1 Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Microcirculation; Nitric Oxide; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Skin; Thiazolidinediones; Vasculitis	2006
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:4 Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2006
[Experiences of the DREAM trial]. Orvosi hetilap, 2006, Dec-31, Volume: 147, Issue:52 Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Male; Middle Aged; Prospective Studies; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:9 Topics: Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones: effects on insulin resistance and the cardiovascular system. British journal of pharmacology, 2008, Volume: 153, Issue:4 Topics: Adipokines; Animals; Atherosclerosis; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2008
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Troglitazone	2007
Use of insulin sensitizers in NASH. Endocrinology and metabolism clinics of North America, 2007, Volume: 36, Issue:4 Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone	2007
[Therapy with glitazones--a risk for cardiovascular disease?]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49 Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:3 Topics: Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Pioglitazone; Rosiglitazone; Thiazolidinediones	2008
[Metabolic syndrome, type 1 diabetes mellitus and insulin resistance]. Medicina clinica, 2008, Apr-05, Volume: 130, Issue:12 Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Rosiglitazone; Thiazolidinediones	2008
PPARgamma agonists and coronary atherosclerosis. Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides	2008
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. La Revue de medecine interne, 1999, Volume: 20 Suppl 3 Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	1999
[The development of thiazolidinedione drugs as anti-diabetic agents]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
[Proper usage of thiazolidinediones]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
[Rosiglitazone (BRL-49653)]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides	2000
[PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2000, Volume: 45, Issue:6 Suppl Topics: Animals; Chromans; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2000
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annual review of medicine, 2001, Volume: 52 Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone	2001
[The importance of syndrome X in daily practice]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:6 Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
Insulin resistance and its treatment by thiazolidinediones. Recent progress in hormone research, 2001, Volume: 56 Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents]. Nederlands tijdschrift voor geneeskunde, 2001, Aug-11, Volume: 145, Issue:32 Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
Beta-cell deterioration--prospects for reversal or prevention. Diabetes, obesity & metabolism, 2001, Volume: 3 Suppl 1 Topics: Animals; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Lipids; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2001
Insulin resistance and beta-cell function--a clinical perspective. Diabetes, obesity & metabolism, 2001, Volume: 3 Suppl 1 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2001
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes, obesity & metabolism, 2001, Volume: 3 Suppl 1 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2001
[Medication of the month. Rosiglitazone (Avandia)]. Revue medicale de Liege, 2002, Volume: 57, Issue:4 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain	2002

Trials

127 trial(s) available for rosiglitazone and Insulin Resistance

Article	Year
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2020, Volume: 36, Issue:4 Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; India; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Spironolactone; Treatment Outcome; Young Adult	2020
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertility and sterility, 2020, Volume: 113, Issue:1 Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Treatment Outcome; Waist Circumference; Young Adult	2020
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. Pediatric diabetes, 2020, Volume: 21, Issue:4 Topics: Adolescent; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucokinase; Hepatocyte Nuclear Factor 4; Humans; Insulin Resistance; Insulin-Secreting Cells; Life Style; Longitudinal Studies; Male; Metformin; Mutation; Pediatric Obesity; Risk Reduction Behavior; Rosiglitazone	2020
Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial. Diabetes care, 2021, Volume: 44, Issue:1 Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rosiglitazone	2021
Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7 Topics: Aged; Blood Glucose; Blood Pressure; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Rest; Rosiglitazone	2018
Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. The Journal of clinical endocrinology and metabolism, 2018, 06-01, Volume: 103, Issue:6 Topics: Adolescent; Androgens; Aspartate Aminotransferases; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Estradiol; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Menstruation Disturbances; Metformin; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone	2018
Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PloS one, 2013, Volume: 8, Issue:4 Topics: Abdominal Fat; Blood Glucose; Body Composition; Double-Blind Method; Female; Glucose Tolerance Test; HIV Infections; Homeostasis; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism; Male; Middle Aged; Placebos; Recombinant Proteins; Rosiglitazone; Thiazolidinediones	2013
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clinic proceedings, 2014, Volume: 89, Issue:6 Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2014
The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial. Antiviral therapy, 2016, Volume: 21, Issue:2 Topics: Body Composition; Double-Blind Method; Fatty Liver; Female; Growth Hormone; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor I; Intra-Abdominal Fat; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2016
The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes research and clinical practice, 2008, Volume: 81, Issue:2 Topics: Adult; Double-Blind Method; Female; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Oxidative Stress; Peroxides; Placebos; Rosiglitazone; Thiazolidinediones	2008
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:8 Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Metformin; Prospective Studies; Reproducibility of Results; Rosiglitazone; Thiazolidinediones	2008
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. The American journal of cardiology, 2008, Jul-01, Volume: 102, Issue:1 Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
[Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2008
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. European journal of endocrinology, 2008, Volume: 159, Issue:4 Topics: Androgens; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Menstrual Cycle; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasodilation	2008
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry, 2009, Volume: 42, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones	2009
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta psychiatrica Scandinavica, 2009, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, LDL; Clozapine; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Placebos; Rosiglitazone; Schizophrenia; Thiazolidinediones	2009
Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. European journal of endocrinology, 2009, Volume: 161, Issue:3 Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Fibroblast Growth Factors; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones	2009
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:1 Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome	2010
A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 297, Issue:5 Topics: Absorptiometry, Photon; Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Body Composition; Calorimetry, Indirect; Double-Blind Method; Glucose; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed	2009
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:1 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Pilot Projects; Pioglitazone; Placebos; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Solubility; Thiazolidinediones	2010
Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:4 Topics: Aged; Body Composition; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome. European heart journal, 2010, Volume: 31, Issue:8 Topics: Double-Blind Method; Forearm; Humans; Insulin Resistance; Ischemia; Metabolic Syndrome; Muscle, Skeletal; Radionuclide Imaging; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2010
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes care, 2010, Volume: 33, Issue:5 Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain	2010
Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy, 2010, Volume: 30, Issue:3 Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones; Time Factors; Waist Circumference	2010
Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9 Topics: Blood Glucose; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Exercise Therapy; Fasting; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Prediabetic State; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2010
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:1 Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxybutyrates; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Netherlands; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides	2011
Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2011, Volume: 119, Issue:2 Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Lipids; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Rosiglitazone; Serpins; Thiazolidinediones	2011
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:3 Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Carbamates; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; KCNQ1 Potassium Channel; Male; Middle Aged; Pharmacogenetics; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones	2011
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5 Topics: Adolescent; Adrenocorticotropic Hormone; Androstenes; Body Composition; Cardiovascular Diseases; Double-Blind Method; Ethinyl Estradiol; Female; Glucose Clamp Technique; Glucose Tolerance Test; Hemodynamics; Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Overweight; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Stimulation, Chemical; Thiazolidinediones	2011
Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:4 Topics: Adult; Amiloride; Cross-Over Studies; Diuretics; Double-Blind Method; Drug Interactions; Epithelial Sodium Channels; Exosomes; Female; Furosemide; Humans; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; Middle Aged; Natriuresis; Rosiglitazone; Thiazolidinediones; Up-Regulation	2011
Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:11 Topics: Adipokines; Adolescent; Adult; Aged; C-Reactive Protein; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Kidney Failure, Chronic; Lipids; Lipoproteins; Male; Middle Aged; Prognosis; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vascular Stiffness; Young Adult	2011
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes, 2011, Volume: 60, Issue:5 Topics: Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones	2011
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chinese medical journal, 2011, Volume: 124, Issue:5 Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Triglycerides; Young Adult	2011
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study. The Journal of international medical research, 2011, Volume: 39, Issue:2 Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Young Adult	2011
A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:4 Topics: Adult; Blood Glucose; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resistance; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult	2012
Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:3 Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Pilot Projects; Polycystic Ovary Syndrome; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones	2012
[Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome]. Zhonghua fu chan ke za zhi, 2002, Volume: 37, Issue:5 Topics: Administration, Oral; Adult; Androstenedione; Blood Glucose; Body Weight; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Lipids; Luteinizing Hormone; Menstruation; Neuropeptide Y; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazoles; Thiazolidinediones; Treatment Outcome	2002
Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. Journal of acquired immune deficiency syndromes (1999), 2002, Oct-01, Volume: 31, Issue:2 Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Female; Glucose; Glucose Clamp Technique; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pilot Projects; Radiography; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome	2002
Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes care, 2003, Volume: 26, Issue:1 Topics: Aged; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. Journal of the Society for Gynecologic Investigation, 2003, Volume: 10, Issue:2 Topics: Adult; Area Under Curve; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Luteinizing Hormone; Menstruation; Polycystic Ovary Syndrome; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertility and sterility, 2003, Volume: 79, Issue:3 Topics: Adolescent; Adult; Blood Glucose; Clomiphene; Deamino Arginine Vasopressin; Dehydroepiandrosterone Sulfate; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ovulation Induction; Placebos; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazoles; Thiazolidinediones	2003
Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2003, Volume: 38, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Middle Aged; Patient Dropouts; Pilot Projects; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome	2003
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes, 2003, Volume: 52, Issue:8 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoenzymes; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones	2003
Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antiviral therapy, 2003, Volume: 8, Issue:3 Topics: Adult; Antiretroviral Therapy, Highly Active; Body Composition; Cholesterol; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Triglycerides	2003
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Biopsy; Fatty Liver; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2003
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology, 2003, Nov-19, Volume: 42, Issue:10 Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Endothelium, Vascular; Female; Fibrinogen; Humans; Insulin Resistance; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilator Agents	2003
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes care, 2004, Volume: 27, Issue:2 Topics: Acetylcholine; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Fasting; Female; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Reference Values; Rosiglitazone; Thiazolidinediones	2004
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. American journal of physiology. Endocrinology and metabolism, 2004, Volume: 286, Issue:6 Topics: Adiponectin; Adipose Tissue; Antiretroviral Therapy, Highly Active; Body Composition; Fatty Acids; Gene Expression; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Liver; Proteins; Rosiglitazone; Subcutaneous Tissue; Thiazolidinediones	2004
Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2. Arzneimittel-Forschung, 2004, Volume: 54, Issue:1 Topics: Adult; Aged; Area Under Curve; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lactation; Liver; Male; Metformin; Middle Aged; Pregnancy; Rosiglitazone; Tablets; Thiazolidinediones	2004
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cohort Studies; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Insulin Resistance; Lipids; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Ultrasonography; Weight Gain	2004
Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertility and sterility, 2004, Volume: 81, Issue:3 Topics: Adolescent; Adult; Body Mass Index; Female; Glucose Tolerance Test; Growth Substances; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Luteinizing Hormone; Menstruation; Polycystic Ovary Syndrome; Pregnancy; Prospective Studies; Reproduction; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2004
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:5 Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Glucose Clamp Technique; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Postprandial Period; Rosiglitazone; Thiazolidinediones	2004
[Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome]. Zhonghua fu chan ke za zhi, 2004, Volume: 39, Issue:3 Topics: Adult; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ovulation Induction; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2004
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Annals of internal medicine, 2004, May-18, Volume: 140, Issue:10 Topics: Adiponectin; Adult; Double-Blind Method; Fatty Acids, Nonesterified; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2004
Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2004
Evidence for a potent antiinflammatory effect of rosiglitazone. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I-kappa B Proteins; Insulin; Insulin Resistance; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Obesity; Rosiglitazone; Solubility; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha	2004
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. American heart journal, 2004, Volume: 147, Issue:6 Topics: Blood Platelets; Coronary Disease; Diabetes Complications; Double-Blind Method; Female; Humans; Insulin Resistance; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Count; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2004
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. Journal of cardiovascular pharmacology, 2004, Volume: 44, Issue:2 Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation	2004
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 2004, Volume: 53, Issue:8 Topics: Adipose Tissue; Cholesterol; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Triglycerides	2004
Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. Journal of hypertension, 2004, Volume: 22, Issue:9 Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2004
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Human pathology, 2004, Volume: 35, Issue:9 Topics: Biopsy; Blood Glucose; Fatty Liver; Female; Fibrosis; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Function Tests; Male; Middle Aged; Obesity; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Transcription Factors	2004
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and sterility, 2004, Volume: 82, Issue:4 Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Venezuela	2004
Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism: clinical and experimental, 2004, Volume: 53, Issue:12 Topics: Adiponectin; Adult; Black or African American; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Intercellular Signaling Peptides and Proteins; Islets of Langerhans; Lipids; Longitudinal Studies; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones	2004
Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:2 Topics: Blood Glucose; Endothelium, Vascular; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Kidney Transplantation; Male; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Human reproduction (Oxford, England), 2005, Volume: 20, Issue:4 Topics: Adult; Anovulation; Blood Glucose; Body Weight; Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Vitamin B 12	2005
Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clinical endocrinology, 2005, Volume: 62, Issue:1 Topics: Adult; Aged; Blood Glucose; C-Peptide; Chi-Square Distribution; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sex Factors; Single-Blind Method; Thiazolidinediones; Treatment Outcome	2005
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension]. Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:12 Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones	2004
The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:3 Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Homeostasis; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones	2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antiviral therapy, 2005, Volume: 10, Issue:1 Topics: Adult; Anti-HIV Agents; Australia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation	2005
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. American journal of hypertension, 2005, Volume: 18, Issue:2 Pt 1 Topics: Aged; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Electrolytes; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2005
The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:4 Topics: Adult; Apolipoproteins B; Biomarkers; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. European journal of endocrinology, 2005, Volume: 153, Issue:1 Topics: Adult; Biomarkers; Body Weight; C-Reactive Protein; Endothelium, Vascular; Female; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Smooth, Vascular; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasculitis	2005
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Human reproduction (Oxford, England), 2005, Volume: 20, Issue:12 Topics: Adult; Androgens; Antioxidants; Blood Glucose; Body Mass Index; Body Weight; Female; Homeostasis; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Malondialdehyde; Metformin; Models, Statistical; Oxidative Stress; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Time Factors	2005
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes, 2005, Volume: 54, Issue:9 Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Myocardium; Rosiglitazone; Thiazolidinediones	2005
Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes research and clinical practice, 2005, Volume: 70, Issue:1 Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Triglycerides	2005
Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:1 Topics: Blood Glucose; Female; Hemorrhage; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Luteinizing Hormone; Menstruation; Ovary; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Vagina	2006
Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:4 Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain	2005
Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:12 Topics: Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Perfusion; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow; Rosiglitazone; Subcutaneous Tissue; Thiazolidinediones	2005
Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:1 Topics: Adolescent; Adult; Androgens; Blood Glucose; Cholesterol, HDL; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Insulin; Insulin Resistance; Middle Aged; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones	2006
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2005, Volume: 14, Issue:3 Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Protease Inhibitors; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:11 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Cognition Disorders; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mental Recall; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Pilot Projects; PPAR gamma; Retention, Psychology; Rosiglitazone; Thiazolidinediones	2005
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clinical therapeutics, 2005, Volume: 27, Issue:9 Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors	2005
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes & vascular disease research, 2005, Volume: 2, Issue:1 Topics: Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Selectins; Thiazolidinediones	2005
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:1 Topics: Adiponectin; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Proinsulin; Prospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2006
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:3 Topics: Adiponectin; Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Receptors, Tumor Necrosis Factor, Type II; Resistin; Rosiglitazone; Thiazolidinediones	2006
Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. European journal of obstetrics, gynecology, and reproductive biology, 2006, May-01, Volume: 126, Issue:1 Topics: Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Waist-Hip Ratio	2006
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:1 Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides	2006
The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2006, Volume: 12, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Homeostasis; Humans; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tissue Plasminogen Activator	2006
Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes care, 2006, Volume: 29, Issue:3 Topics: Adult; Blood Pressure; Capillary Permeability; Edema; Female; Forearm; Humans; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; omega-N-Methylarginine; Plasma Volume; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasodilation	2006
Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:4 Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus; Disease Progression; Female; Glucose Intolerance; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
Prevention of type 2 diabetes in the prediabetic population. Journal of the Indian Medical Association, 2005, Volume: 103, Issue:11 Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Prediabetic State; Risk Factors; Rosiglitazone; Thiazolidinediones	2005
Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection, 2006, Volume: 34, Issue:2 Topics: Adult; Antiretroviral Therapy, Highly Active; Body Composition; Female; Glucose Tolerance Test; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
Free fatty acids normalize a rosiglitazone-induced visfatin release. American journal of physiology. Endocrinology and metabolism, 2006, Volume: 291, Issue:5 Topics: Adipocytes; Adult; Anticoagulants; Cells, Cultured; Cytokines; Drug Interactions; Fatty Acids, Nonesterified; Heparin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Nicotinamide Phosphoribosyltransferase; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides	2006
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Current medical research and opinion, 2006, Volume: 22, Issue:9 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2006
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:6 Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome	2006
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:9 Topics: Acanthosis Nigricans; Administration, Oral; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Obesity; Pilot Projects; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:12 Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; North America; Racial Groups; Rosiglitazone; Sex Distribution; Thiazolidinediones	2006
Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism: clinical and experimental, 2007, Volume: 56, Issue:1 Topics: Black People; Blood Glucose; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Liver; Longitudinal Studies; Middle Aged; Pilot Projects; Rosiglitazone; Thiazolidinediones	2007
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical endocrinology, 2007, Volume: 66, Issue:2 Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Administration Schedule; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-18; Interleukin-6; Metformin; Multivariate Analysis; Resistin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha	2007
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:4 Topics: Adiponectin; Adipose Tissue; Adult; Cytokines; Female; HIV Seropositivity; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Regression Analysis; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. European journal of endocrinology, 2007, Volume: 156, Issue:2 Topics: Adiponectin; Adult; Female; Ghrelin; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Peptide Hormones; Placebos; Polycystic Ovary Syndrome; Resistin; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. Journal of internal medicine, 2007, Volume: 261, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima	2007
Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. International journal of obesity (2005), 2007, Volume: 31, Issue:8 Topics: Biopsy; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Transcription Factors	2007
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones	2007
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Irbesartan; Leptin; Lipids; Male; Middle Aged; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha	2006
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:6 Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss	2008
Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:7 Topics: Acetylcholine; Adult; Anticoagulants; Arginine; C-Reactive Protein; Endothelium, Vascular; Fatty Acids, Nonesterified; Forearm; Heparin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Methylation; Nitroglycerin; Plethysmography; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasculitis; Vasodilation; Vasodilator Agents	2007
Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clinical endocrinology, 2007, Volume: 67, Issue:3 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenocorticotropic Hormone; Blood Glucose; Enzyme Activation; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones	2007
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes care, 2007, Volume: 30, Issue:10 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood pressure, 2007, Volume: 16, Issue:2 Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2007
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:8 Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult	2008
A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus. American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:5 Topics: Diabetes Mellitus, Type 2; Exercise Test; Female; Glucose; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Physical Exertion; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2007
[The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report]. Przeglad lekarski, 2007, Volume: 64, Issue:2 Topics: Adiponectin; Adolescent; Adult; Body Mass Index; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Middle Aged; Obesity; Polycystic Ovary Syndrome; Resistin; Rosiglitazone; Thiazolidinediones; Triglycerides	2007
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18 Topics: Adult; Female; Follow-Up Studies; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Particle Size; PPAR gamma; Rosiglitazone; Thiazolidinediones	2007
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croatian medical journal, 2007, Volume: 48, Issue:6 Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Administration Schedule; Fasting; Follow-Up Studies; Glucose Tolerance Test; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Prospective Studies; Protease Inhibitors; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome	2007
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:1 Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2008
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Single-Blind Method; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides	2008
Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clinical science (London, England : 1979), 2008, Volume: 115, Issue:6 Topics: Adiponectin; Adult; Blood Glucose; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Molecular Weight; Protein Isoforms; Rosiglitazone; Thiazolidinediones; Viral Load	2008
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. European journal of endocrinology, 2008, Volume: 158, Issue:6 Topics: Adolescent; Adult; Analysis of Variance; Androgens; Female; Gene Expression; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors	2008
Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:4 Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Single-Blind Method; Thiazolidinediones	2008
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Archives of medical research, 2008, Volume: 39, Issue:4 Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Leptin; Male; Metformin; Middle Aged; Obesity; Overweight; Resistin; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tumor Necrosis Factor-alpha	2008
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2008
The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatric diabetes, 2008, Jul-28, Volume: 9, Issue:4 Pt 1 Topics: Adiponectin; Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2008
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, 2008, Volume: 135, Issue:1 Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Fatty Liver; Female; Fibrosis; gamma-Glutamyltransferase; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Necrosis; Placebos; Rosiglitazone; Thiazolidinediones	2008
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes care, 2001, Volume: 24, Issue:2 Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	2001
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology, 2002, Volume: 143, Issue:3 Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002

Other Studies

334 other study(ies) available for rosiglitazone and Insulin Resistance

Article	Year
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. Journal of medicinal chemistry, 2001, Aug-02, Volume: 44, Issue:16 Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Mice; Oxazines; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors; Triglycerides	2001
Phenylacetic acid derivatives as hPPAR agonists. Bioorganic & medicinal chemistry letters, 2003, Apr-07, Volume: 13, Issue:7 Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Drug Design; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Phenylacetates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides	2003
Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. Journal of medicinal chemistry, 2006, Jul-13, Volume: 49, Issue:14 Topics: Adipocytes; Adipogenesis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug Design; Humans; Hypolipidemic Agents; Insulin Resistance; Interleukins; Keratinocytes; Models, Molecular; Molecular Structure; Phenylacetates; PPAR gamma; Rats; Rats, Zucker; Structure-Activity Relationship; Thiazolidinediones; Thioctic Acid	2006
Indanylacetic acids as PPAR-delta activator insulin sensitizers. Bioorganic & medicinal chemistry letters, 2007, Aug-01, Volume: 17, Issue:15 Topics: Fluorescence Resonance Energy Transfer; Insulin Resistance; PPAR delta; Structure-Activity Relationship	2007
Design, synthesis and insulin-sensitizing activity of indomethacin and diclofenac derivatives. Bioorganic & medicinal chemistry letters, 2009, Jun-15, Volume: 19, Issue:12 Topics: 3T3-L1 Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cyclooxygenase Inhibitors; Diclofenac; Drug Design; Indomethacin; Insulin; Insulin Resistance; Mice; PPAR gamma; Rats	2009
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. Journal of medicinal chemistry, 2011, Feb-10, Volume: 54, Issue:3 Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Crystallography, X-Ray; Diabetes Mellitus; Dogs; ERRalpha Estrogen-Related Receptor; Ethers; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Macaca fascicularis; Male; Mice; Mice, Knockout; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Thiazolidinediones; Triglycerides	2011
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Partial Agonism; Drug Screening Assays, Antitumor; Fibric Acids; Fibroblasts; Gene Expression Profiling; Humans; Insulin Resistance; Intra-Abdominal Fat; Liver; Mice; Mice, Inbred C57BL; Models, Molecular; PPAR alpha; PPAR gamma; Propionates; Stereoisomerism; Structure-Activity Relationship; Urea	2012
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22 Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides	2012
Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity. Bioorganic & medicinal chemistry, 2013, Feb-15, Volume: 21, Issue:4 Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Half-Life; Insulin Resistance; Male; Mice; PPAR gamma; Protein Structure, Tertiary; Quinolines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Structure-Activity Relationship; Sulfonamides	2013
Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors. Bioorganic & medicinal chemistry letters, 2013, Apr-15, Volume: 23, Issue:8 Topics: Animals; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Insulin; Insulin Resistance; Mice; Models, Molecular; Molecular Conformation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Recombinant Proteins; Structure-Activity Relationship; Sulfathiazoles	2013
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents. Journal of natural products, 2016, 05-27, Volume: 79, Issue:5 Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Molecular Structure; Murraya; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin	2016
A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A European journal of medicinal chemistry, 2017, Feb-15, Volume: 127 Topics: Adipose Tissue; Alanine Transaminase; alpha-Glucosidases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Weight; Female; Ganoderma; Glycogen; Glycoside Hydrolase Inhibitors; Hydroquinones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Kinetics; Liver; Male; Mice; Molecular Docking Simulation; Protein Conformation	2017
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity. European journal of medicinal chemistry, 2017, Feb-15, Volume: 127 Topics: Antineoplastic Agents; Benzhydryl Compounds; beta Catenin; Carnitine; Cell Proliferation; Drug Evaluation, Preclinical; Hep G2 Cells; HT29 Cells; Humans; Insulin Resistance; Mitochondria; Molecular Docking Simulation; PPAR alpha; PPAR gamma; Protein Conformation; Signal Transduction	2017
Baicalin and its metabolites suppresses gluconeogenesis through activation of AMPK or AKT in insulin resistant HepG-2 cells. European journal of medicinal chemistry, 2017, Dec-01, Volume: 141 Topics: AMP-Activated Protein Kinases; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Gluconeogenesis; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Molecular Structure; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Tumor Cells, Cultured	2017
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. Bioorganic & medicinal chemistry, 2018, 12-01, Volume: 26, Issue:22 Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones	2018
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity. European journal of medicinal chemistry, 2022, May-05, Volume: 235 Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipids; Peroxisome Proliferator-Activated Receptors; PPAR gamma	2022
Long-Term High-Fat Diet Decreases Renal Insulin-Degrading Enzyme Expression and Function by Inhibiting the PPARγ Pathway. Molecular nutrition & food research, 2023, Volume: 67, Issue:7 Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Insulin; Insulin Resistance; Insulysin; Kidney; Mice; Mice, Inbred C57BL; Mice, Obese; Palmitic Acid; PPAR gamma; RNA, Messenger; Rosiglitazone	2023
Identification of a Paracrine Signaling Mechanism Linking CD34 Cell reports, 2019, 10-08, Volume: 29, Issue:2 Topics: Adipogenesis; Adipose Tissue, White; Animals; Antigens, CD34; Bone Morphogenetic Protein 4; Fibroblasts; Insulin Resistance; Intra-Abdominal Fat; Male; Mice, Inbred C57BL; Muscle, Smooth; Paracrine Communication; Phenotype; Rosiglitazone; Signal Transduction; Solubility; Stem Cells; Weight Gain	2019
Heterozygous deletion of Seipin in islet beta cells of male mice has an impact on insulin synthesis and secretion through reduced PPARγ expression. Diabetologia, 2020, Volume: 63, Issue:2 Topics: Adipose Tissue; Animals; Female; GTP-Binding Protein gamma Subunits; Insulin; Insulin Resistance; Islets of Langerhans; Lipodystrophy; Lipodystrophy, Congenital Generalized; Male; Mice; PPAR gamma; Rosiglitazone	2020
American journal of physiology. Endocrinology and metabolism, 2020, 10-01, Volume: 319, Issue:4 Topics: Adipocytes, Brown; Adipocytes, White; Animals; Blood Glucose; Cells, Cultured; Fatty Acid-Binding Proteins; Gene Regulatory Networks; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolomics; Mice; MicroRNAs; Oligopeptides; Organelle Biogenesis; PPAR gamma; Rosiglitazone	2020
Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids. Life sciences, 2020, Oct-15, Volume: 259 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; beta Catenin; Cell Differentiation; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Insulin; Insulin Resistance; Mice; Molecular Docking Simulation; Phthalimides; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones	2020
Adipocytes fail to maintain cellular identity during obesity due to reduced PPARγ activity and elevated TGFβ-SMAD signaling. Molecular metabolism, 2020, Volume: 42 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue; Animals; Cell Differentiation; Diet, High-Fat; Humans; Insulin; Insulin Resistance; Mice; Mice, Inbred C57BL; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Signal Transduction; Smad Proteins; Transforming Growth Factor beta	2020
Rosiglitazone ameliorates skeletal muscle insulin resistance by decreasing free fatty acids release from adipocytes. Biochemical and biophysical research communications, 2020, 12-17, Volume: 533, Issue:4 Topics: 3T3-L1 Cells; Adipocytes; Animals; Asialoglycoproteins; Cell Communication; Coculture Techniques; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin Resistance; Lectins, C-Type; Lipase; Lipid Metabolism; Lipolysis; Membrane Proteins; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Rosiglitazone; Sterol Esterase	2020
Autotaxin Is Regulated by Glucose and Insulin in Adipocytes. Endocrinology, 2017, 04-01, Volume: 158, Issue:4 Topics: 3T3-L1 Cells; Adipocytes; Animals; Dose-Response Relationship, Drug; Glucose; Insulin; Insulin Resistance; Mice; Phosphoric Diester Hydrolases; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors	2017
Insulin Resistance Disrupts the Interaction Between AKT and the NMDA Receptor and the Inactivation of the CaMKIV/CREB Pathway in Minimal Hepatic Encephalopathy. Toxicological sciences : an official journal of the Society of Toxicology, 2017, 10-01, Volume: 159, Issue:2 Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Hepatic Encephalopathy; Hippocampus; Hypoglycemic Agents; Insulin Resistance; Maze Learning; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Receptors, N-Methyl-D-Aspartate; Rosiglitazone; Thiazolidinediones	2017
PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease. Experimental neurology, 2017, Volume: 295 Topics: Alzheimer Disease; Amino Acid Sequence; Animals; Axons; Dentate Gyrus; Female; Fibroblast Growth Factors; HEK293 Cells; Humans; Insulin Resistance; Male; Mice; Mice, Knockout; Mutation; Phosphorylation; PPAR gamma; Rosiglitazone; Sodium Channels; Thiazolidinediones	2017
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Experimental physiology, 2017, 08-01, Volume: 102, Issue:8 Topics: Acetophenones; Adipose Tissue; Animals; Anion Transport Proteins; Diet, High-Fat; Hypoglycemic Agents; Insulin; Insulin Resistance; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Pioglitazone; PPAR gamma; Proprotein Convertase 2; Rosiglitazone; Thiazolidinediones	2017
Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome. Endocrinology, 2017, 09-01, Volume: 158, Issue:9 Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Disease Models, Animal; Glucose; Insulin Resistance; Linoleic Acids, Conjugated; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones	2017
Circulating ApoJ is closely associated with insulin resistance in human subjects. Metabolism: clinical and experimental, 2018, Volume: 78 Topics: Blood Glucose; Clusterin; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones	2018
Codonopsis lanceolata Water Extract Increases Hepatic Insulin Sensitivity in Rats with Experimentally-Induced Type 2 Diabetes. Nutrients, 2017, Nov-01, Volume: 9, Issue:11 Topics: 3T3-L1 Cells; Adiposity; Animals; Biomarkers; Blood Glucose; Codonopsis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Metabolism; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Pancreatectomy; Phosphorylation; Phytotherapy; Plant Extracts; Plants, Medicinal; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Solvents; Thiazolidinediones; Time Factors; Water	2017
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg. Frontiers in immunology, 2018, Volume: 9 Topics: Animals; Antigen-Presenting Cells; Aorta; Cell Plasticity; Endothelial Cells; GATA3 Transcription Factor; Histone Deacetylase 6; Humans; Insulin Resistance; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, Knockout, ApoE; Proto-Oncogene Proteins c-bcl-6; Psoriasis; Rosiglitazone; T-Lymphocytes, Regulatory; Th1 Cells	2018
PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. Biochemical and biophysical research communications, 2018, 04-15, Volume: 498, Issue:4 Topics: Animals; Cell Line; Culture Media, Conditioned; Hepatocytes; Insulin Resistance; Janus Kinase 2; Kupffer Cells; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rosiglitazone; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Thiazolidinediones	2018
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus. Life sciences, 2018, Jul-15, Volume: 205 Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Hypoglycemic Agents; Insulin Resistance; Male; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Spectrophotometry, Atomic; Thiazolidinediones; Trace Elements	2018
An Hsp20-FBXO4 Axis Regulates Adipocyte Function through Modulating PPARγ Ubiquitination. Cell reports, 2018, 06-19, Volume: 23, Issue:12 Topics: Adipocytes; Adipose Tissue, White; Adiposity; Animals; Cold Temperature; Energy Metabolism; F-Box Proteins; Glucose; HSP20 Heat-Shock Proteins; Inflammation; Insulin Resistance; Lipid Metabolism; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR gamma; Protein Stability; RNA, Messenger; Rosiglitazone; Ubiquitination	2018
PPARγ is a major regulator of branched-chain amino acid blood levels and catabolism in white and brown adipose tissues. Metabolism: clinical and experimental, 2018, Volume: 89 Topics: Adipose Tissue, Brown; Adipose Tissue, White; Amino Acids, Branched-Chain; Animals; Chymotrypsin; Diet, High-Fat; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Triglycerides	2018
The Phosphorylation of IRS1 Lipids, 2019, Volume: 54, Issue:2-3 Topics: Animals; Catechin; Cell Line; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Muscle Fibers, Skeletal; Palmitates; Phosphorylation; Proto-Oncogene Proteins c-akt; Rosiglitazone; Tea	2019
Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytotherapy research : PTR, 2014, Volume: 28, Issue:3 Topics: 11-beta-Hydroxysteroid Dehydrogenases; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diet, High-Fat; Dyslipidemias; Fatty Acid Synthases; Fatty Acids; Fruit; Glucose; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Momordica charantia; Phosphoenolpyruvate Carboxykinase (ATP); Phosphorylation; Plant Extracts; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Triglycerides	2014
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PloS one, 2013, Volume: 8, Issue:4 Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin; Insulin Resistance; Interleukin-1 Receptor-Associated Kinases; Leptin; Macrophages; Mice; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptors; Plaque, Atherosclerotic; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2013
The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity. Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:6 Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue; Adiposity; Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Body Mass Index; Cell Differentiation; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Middle Aged; Obesity; Omentum; PPAR gamma; Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2013
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes. Yonsei medical journal, 2013, Volume: 54, Issue:5 Topics: Adiponectin; Adiposity; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; Male; Piperidines; Pyrazoles; Rats; Rats, Inbred OLETF; Receptor, Cannabinoid, CB1; Rimonabant; Rosiglitazone; Thiazolidinediones	2013
A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia, 2013, Volume: 56, Issue:11 Topics: Acute-Phase Proteins; Adipocytes; Adipose Tissue; Adult; Animals; Carrier Proteins; Humans; In Vitro Techniques; Inflammation; Insulin Resistance; Lipopolysaccharides; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2013
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression. International journal of obesity (2005), 2014, Volume: 38, Issue:5 Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, High-Fat; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Genes, p53; Humans; Inflammation; Insulin Resistance; Male; Metformin; Mice; Mice, Knockout; Obesity; Omentum; Rosiglitazone; Thiazolidinediones	2014
Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase. Pharmaceutical biology, 2014, Volume: 52, Issue:1 Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Glucose; Hypoglycemic Agents; Immunoblotting; Insulin; Insulin Resistance; Muscle Fibers, Skeletal; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Thiazolidinediones; Up-Regulation; Xanthenes; Xanthones	2014
Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin. Medical hypotheses, 2013, Volume: 81, Issue:6 Topics: Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Models, Biological; Resistin; Rosiglitazone; Thiazolidinediones	2013
Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PloS one, 2013, Volume: 8, Issue:10 Topics: Adipocytes; Aminopyridines; Animals; Diabetes Mellitus, Type 2; Drug Discovery; Glucose; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Mice, Mutant Strains; Rosiglitazone; Sulfonamides; Thiazolidinediones	2013
Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice. Bioscience, biotechnology, and biochemistry, 2013, Volume: 77, Issue:11 Topics: Animals; Blood Glucose; Body Weight; Chondroitin Sulfates; Diet, High-Fat; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Glucose Tolerance Test; Glucose-6-Phosphatase; Glycogen; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hexokinase; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyruvate Kinase; Receptor, Insulin; Rosiglitazone; Sea Cucumbers; Signal Transduction; Thiazolidinediones	2013
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model. Journal of medicinal food, 2013, Volume: 16, Issue:12 Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones	2013
Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism. Endocrinology, 2014, Volume: 155, Issue:3 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Eye Proteins; Gene Expression Regulation; Glucose Clamp Technique; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Nerve Growth Factors; Phosphorylation; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Serpins; Thiazolidinediones	2014
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PloS one, 2014, Volume: 9, Issue:1 Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides	2014
Midkine, a potential link between obesity and insulin resistance. PloS one, 2014, Volume: 9, Issue:2 Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cytokines; Female; Glucose Transporter Type 4; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Middle Aged; Midkine; Obesity; Phosphorylation; Rosiglitazone; Signal Transduction; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones; Tumor Necrosis Factor-alpha	2014
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PloS one, 2014, Volume: 9, Issue:2 Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2014
Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance. Andrologia, 2015, Volume: 47, Issue:2 Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Exenatide; Glucagon-Like Peptide-1 Receptor; Insulin Resistance; Male; Peptides; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Glucagon; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Venoms	2015
CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo. PloS one, 2014, Volume: 9, Issue:7 Topics: 3T3-L1 Cells; Adipose Tissue, White; Aminopyridines; Animals; Anti-Inflammatory Agents; Cell Differentiation; Cell Polarity; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation	2014
Rosiglitazone inhibits hepatic insulin resistance induced by chronic pancreatitis and IKK-β/NF-κB expression in liver. Pancreas, 2014, Volume: 43, Issue:8 Topics: Anilides; Animals; Drug Evaluation, Preclinical; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Hepatocytes; I-kappa B Kinase; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Pancreatitis, Chronic; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA	2014
PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding. The Journal of clinical investigation, 2014, Volume: 124, Issue:9 Topics: Anilides; Animals; Diet, High-Fat; Energy Metabolism; Female; Glucose; Hyperphagia; Insulin Resistance; Leptin; Male; Mice; Motor Activity; Neurons; PPAR gamma; Pro-Opiomelanocortin; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones	2014
Phosphatase and tension homolog overexpression in insulin resistant diabetic adipose tissue. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2014, Volume: 29, Issue:3 Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Mice; Mice, Inbred C57BL; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones	2014
Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs. Journal of proteome research, 2014, Dec-05, Volume: 13, Issue:12 Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression Profiling; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Networks and Pathways; Metabolomics; Mice, Inbred C57BL; Obesity; Proteomics; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones; Transcriptome	2014
PPARγ gene expression is autoregulated in primary adipocytes: ligand, sumoylation, and isoform specificity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015, Volume: 47, Issue:2 Topics: Adipocytes; Amino Acid Substitution; Animals; Cells, Cultured; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Models, Biological; Mutation, Missense; PPAR gamma; Protein Isoforms; Rats; Rosiglitazone; Sumoylation; Thiazolidinediones	2015
Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells. Cell biochemistry and function, 2014, Volume: 32, Issue:8 Topics: Anilides; Animals; Apoptosis; Cell Line; Cell Survival; Enzyme Inhibitors; Hypoglycemic Agents; Insulin Resistance; Mice; Myoblasts, Skeletal; Palmitates; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rosiglitazone; Thiazolidinediones	2014
ATF3 inhibits PPARγ-stimulated transactivation in adipocyte cells. Biochemical and biophysical research communications, 2015, Jan-02, Volume: 456, Issue:1 Topics: 3T3-L1 Cells; Activating Transcription Factor 3; Adipocytes; Animals; Cell Differentiation; Chromatin Immunoprecipitation; Fatty Acid-Binding Proteins; Genes, Reporter; Insulin Resistance; Mice; p300-CBP Transcription Factors; PPAR gamma; Promoter Regions, Genetic; Protein Binding; Rosiglitazone; Thiazolidinediones; Transcriptional Activation	2015
Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiology of aging, 2015, Volume: 36, Issue:3 Topics: Administration, Oral; Animals; Brain-Derived Neurotrophic Factor; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression; Hippocampus; Hypoglycemic Agents; Injections, Intraventricular; Insulin Resistance; Male; Memory; Mice, Inbred C57BL; Molecular Targeted Therapy; Neuronal Plasticity; PPAR gamma; Rosiglitazone; Thiazolidinediones	2015
Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-α. Anais da Academia Brasileira de Ciencias, 2014, Volume: 86, Issue:4 Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Dyslipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones; Tumor Necrosis Factor-alpha; Xanthones	2014
Acute Hepatic Insulin Resistance Contributes to Hyperglycemia in Rats Following Myocardial Infarction. Molecular medicine (Cambridge, Mass.), 2015, Feb-23, Volume: 21 Topics: Animals; Blood Glucose; Gluconeogenesis; Hyperglycemia; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Myocardial Infarction; Rats; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha	2015
Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice. PloS one, 2015, Volume: 10, Issue:3 Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Diabetes Mellitus, Experimental; Fasting; Female; Gene Expression Regulation; Glucose Tolerance Test; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Pregnancy; Rosiglitazone; Thiazolidinediones	2015
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:7 Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucocorticoids; Hydrolysis; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides; Troglitazone	2015
Rosiglitazone, but not epigallocatechin-3-gallate, attenuates the decrease in PGC-1α protein levels in palmitate-induced insulin-resistant C2C12 cells. Lipids, 2015, Volume: 50, Issue:6 Topics: Animals; Antioxidants; Catechin; Cell Line; Creatine Kinase; Glucose; Hypoglycemic Agents; Insulin Resistance; Mice; Muscle Fibers, Skeletal; Myoblasts; Palmitates; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rosiglitazone; Thiazolidinediones; Transcription Factors	2015
PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes. Biochemical and biophysical research communications, 2015, Aug-28, Volume: 464, Issue:3 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones	2015
Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Molecular endocrinology (Baltimore, Md.), 2015, Volume: 29, Issue:9 Topics: Adipocytes, White; Adipose Tissue, Brown; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; PPAR gamma; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Ubiquitin-Conjugating Enzymes	2015
Fucoidan from sea cucumber Cucumaria frondosa exhibits anti-hyperglycemic effects in insulin resistant mice via activating the PI3K/PKB pathway and GLUT4. Journal of bioscience and bioengineering, 2016, Volume: 121, Issue:1 Topics: Adipose Tissue; Animals; Blood Glucose; Cell Membrane; Cucumaria; Diet; Diet, High-Fat; Enzyme Activation; Fasting; Glucose Tolerance Test; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Phosphatidylinositol 3-Kinase; Phosphorylation; Polysaccharides; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazolidinediones	2016
Effects of PPARγ agonist on heart rate variability and cardiac mitochondrial function in obese-insulin resistant rats. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Animals; Heart Rate; Insulin Resistance; Male; Mitochondria, Heart; Obesity; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2015
Padina arborescens Ameliorates Hyperglycemia and Dyslipidemia in C57BL/KsJ-db/db Mice, a Model of Type 2 Diabetes Mellitus. Journal of medicinal food, 2015, Volume: 18, Issue:10 Topics: Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dyslipidemias; Fasting; Glucose Tolerance Test; Glycated Hemoglobin; Glycogen; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Phaeophyceae; Rosiglitazone; Thiazolidinediones	2015
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep. Endocrinology, 2016, Volume: 157, Issue:2 Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resistance; Obesity; Polycystic Ovary Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Rosiglitazone; Sheep; Testosterone; Thiazolidinediones	2016
Protective Effects of Red Guava on Inflammation and Oxidative Stress in Streptozotocin-Induced Diabetic Mice. Molecules (Basel, Switzerland), 2015, Dec-12, Volume: 20, Issue:12 Topics: Animals; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Hyperglycemia; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Oxidative Stress; Plant Extracts; Psidium; Rosiglitazone; Streptozocin; Taiwan; Thiazolidinediones; Tumor Necrosis Factor-alpha	2015
[Effect of Jinlida on DGAT1 in Skeletal Muscle in Fat-Induced Insulin Resistance ApoE -/- Mice]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2015, Volume: 38, Issue:6 Topics: Animals; Apolipoproteins E; Blood Glucose; Cholesterol; Diacylglycerol O-Acyltransferase; Diet, High-Fat; Drugs, Chinese Herbal; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones; Triglycerides	2015
Insulin sensitizers prevent fine particulate matter-induced vascular insulin resistance and changes in endothelial progenitor cell homeostasis. American journal of physiology. Heart and circulatory physiology, 2016, 06-01, Volume: 310, Issue:11 Topics: Animals; Aorta; Ataxin-1; Caspase 1; Cells, Cultured; Diet, High-Fat; Endothelial Progenitor Cells; Homeostasis; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Inhalation Exposure; Insulin; Insulin Resistance; Interleukin-18; Interleukin-1beta; Male; Metformin; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Particle Size; Particulate Matter; Phosphorylation; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2016
Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice. Journal of physiology and biochemistry, 2016, Volume: 72, Issue:2 Topics: Animals; Anti-Obesity Agents; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Rosiglitazone; Second Messenger Systems; Thiazolidinediones; Triterpenes; Ursolic Acid; Weight Gain	2016
NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice. Cell reports, 2016, 08-16, Volume: 16, Issue:7 Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Cyclin-Dependent Kinase 5; Cytokines; Fatty Acids, Nonesterified; Female; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Knockout; Muscle, Skeletal; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2016
Bmp4 Promotes a Brown to White-like Adipocyte Shift. Cell reports, 2016, 08-23, Volume: 16, Issue:8 Topics: Adipocytes, Brown; Adipocytes, White; Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Bone Morphogenetic Protein 4; Cell Differentiation; Cell Line, Transformed; Cyclic AMP; Diabetes Mellitus, Type 2; Gene Expression Regulation; Humans; Insulin Resistance; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Smad Proteins; Sterol Esterase; Thiazolidinediones	2016
Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus. American journal of physiology. Endocrinology and metabolism, 2016, 12-01, Volume: 311, Issue:6 Topics: Animals; Blood Glucose; Carbon Isotopes; Diet, High-Fat; Female; Glucose Clamp Technique; Hypoglycemic Agents; Indicators and Reagents; Injections, Intraperitoneal; Injections, Intravenous; Insulin Resistance; Kinetics; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Pilot Projects; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2016
Maternal Obesity Programs Senescence Signaling and Glucose Metabolism in Osteo-Progenitors From Rat and Human. Endocrinology, 2016, Volume: 157, Issue:11 Topics: Adipogenesis; Animals; Cell Proliferation; Cells, Cultured; Cellular Senescence; Female; Glucose; Humans; Insulin Resistance; Male; Mesenchymal Stem Cells; Obesity; Osteogenesis; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Skull; Thiazolidinediones; Thinness	2016
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. European journal of clinical investigation, 2017, Volume: 47, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Cell Line; Cells, Cultured; Chemokines; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Hep G2 Cells; Hepatic Stellate Cells; Hepatocytes; Hepcidins; Humans; Hydrocarbons, Fluorinated; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipocalin-2; Liver; Liver X Receptors; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Sulfonamides; Thiazolidinediones; Waist-Hip Ratio; Young Adult	2017
FAK signalling controls insulin sensitivity through regulation of adipocyte survival. Nature communications, 2017, 02-06, Volume: 8 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Adiposity; Adult; Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Female; Focal Adhesion Kinase 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Middle Aged; Obesity; PPAR gamma; Primary Cell Culture; Rosiglitazone; Signal Transduction; Thiazolidinediones	2017
Cidea is associated with lipid droplets and insulin sensitivity in humans. Proceedings of the National Academy of Sciences of the United States of America, 2008, Jun-03, Volume: 105, Issue:22 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Amino Acid Sequence; Animals; Apoptosis Regulatory Proteins; Body Mass Index; Carrier Proteins; Humans; Insulin Resistance; Lipolysis; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Obesity; Perilipin-1; Phosphoproteins; PPAR gamma; Proteins; RNA Interference; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1. Biochemical and biophysical research communications, 2008, Aug-08, Volume: 372, Issue:4 Topics: Acetylglucosamine; Acylation; Animals; Cell Line; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Protein Processing, Post-Translational; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Transcription, Genetic; Zinc Fingers	2008
A combination of CLA-DAG oil modifies the diabetic phenotype in male Zucker diabetic fatty rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:4 Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diglycerides; DNA, Complementary; Eating; Gene Expression; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney; Linoleic Acid; Liver; Muscle, Skeletal; Myocardium; Phenotype; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Long-term consumption of saponins derived from Platycodi radix (22 years old) enhances hepatic insulin sensitivity and glucose-stimulated insulin secretion in 90 % pancreatectomized diabetic rats fed a high-fat diet. The British journal of nutrition, 2009, Volume: 101, Issue:3 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dietary Fats; Glucose; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Korea; Liver; Male; Pancreatectomy; Plant Extracts; Platycodon; Rats; Rats, Sprague-Dawley; Rosiglitazone; Saponins; Thiazolidinediones; Time Factors	2009
Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3 Topics: Animals; Behavior, Animal; Blood Glucose; Cognition; Dietary Fats; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Maze Learning; Memory; Motor Activity; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors	2008
Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:10 Topics: 3T3-L1 Cells; Adipocytes; Animals; Dexamethasone; Dose-Response Relationship, Drug; Glucocorticoids; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Organometallic Compounds; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Vanadium Compounds	2008
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. The Journal of endocrinology, 2009, Volume: 200, Issue:2 Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Disease Models, Animal; Fructose; Gene Expression; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Myocardium; Rats; Rats, Sprague-Dawley; Rosiglitazone; Streptozocin; Thiazolidinediones	2009
[Use of rosiglitazone in women with polycystic ovarian syndrome]. Akusherstvo i ginekologiia, 2005, Volume: 44, Issue:6 Topics: Adolescent; Adult; Body Mass Index; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Thiazolidinediones	2005
Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47 Topics: Animals; Caspase 1; Disease Models, Animal; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Interleukin-18; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2008
Evaluation of rosiglitazone administration on cardiovascular function in severe obesity. Clinical cardiology, 2008, Volume: 31, Issue:12 Topics: Adult; Blood Pressure; Body Weight; Cardiovascular System; Diastole; Echocardiography, Doppler; Female; Humans; Insulin; Insulin Resistance; Male; Obesity; PPAR gamma; Rosiglitazone; Systole; Thiazolidinediones; Ventricular Function, Left	2008
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, Volume: 23, Issue:6 Topics: Adiponectin; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Chemokine CCL2; Diet; Dietary Fats; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Liver; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Obese; Muscle, Skeletal; Obesity; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones	2009
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3 Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. European journal of pharmacology, 2009, Apr-17, Volume: 608, Issue:1-3 Topics: Adiponectin; Animals; Benzothiazoles; Blood Glucose; Cells, Cultured; Cross-Over Studies; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Gene Expression; Gluconeogenesis; Glucose; Glucose Clamp Technique; Heparin; Hepatocytes; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Liver; Male; Oxidation-Reduction; PPAR gamma; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Saphenous Vein; Thiazolidinediones; Time Factors	2009
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life sciences, 2009, May-08, Volume: 84, Issue:19-20 Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones	2009
IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochemical and biophysical research communications, 2009, May-15, Volume: 382, Issue:4 Topics: 3T3-L1 Cells; Adiponectin; Animals; Cell Hypoxia; Cobalt; Fibroblasts; Genes, Reporter; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Mice; Obesity; PPAR gamma; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha	2009
Anti-diabetic effects of water extract and crude polysaccharides from tuberous root of Liriope spicata var. prolifera in mice. Journal of ethnopharmacology, 2009, Mar-18, Volume: 122, Issue:2 Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liriope Plant; Male; Mice; Mice, Inbred BALB C; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Rosiglitazone; Thiazolidinediones; Triglycerides	2009
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009, Volume: 58, Issue:10 Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Knee Joint; Male; Obesity; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Purines; Rats; Rats, Inbred OLETF; Risk Factors; Rosiglitazone; Thiazolidinediones; Uric Acid	2009
Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice. The Journal of biological chemistry, 2009, May-22, Volume: 284, Issue:21 Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Energy Metabolism; Feeding Behavior; Glucose Intolerance; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Motor Activity; Muscle, Skeletal; Proteins; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Up-Regulation	2009
CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell metabolism, 2009, Volume: 9, Issue:4 Topics: Adipose Tissue; Animals; Chemokine CXCL5; Gene Expression Regulation; Humans; Insulin Resistance; Macrophages; Mice; Obesity; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha	2009
Insulin sensitizing activity of ethyl acetate fraction of Acorus calamus L. in vitro and in vivo. Journal of ethnopharmacology, 2009, Jun-22, Volume: 123, Issue:2 Topics: Acetates; Acorus; Administration, Oral; Animals; Diabetes Mellitus, Experimental; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Medicine, Traditional; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle Fibers, Skeletal; Plant Extracts; Rosiglitazone; Thiazolidinediones; Weight Gain	2009
Neferine enhances insulin sensitivity in insulin resistant rats. Journal of ethnopharmacology, 2009, Jul-06, Volume: 124, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzylisoquinolines; Blood Glucose; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Nelumbo; Obesity; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Rosiglitazone; Seeds; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha	2009
Abelmoschus moschatus (Malvaceae), an aromatic plant, suitable for medical or food uses to improve insulin sensitivity. Phytotherapy research : PTR, 2010, Volume: 24, Issue:2 Topics: Abelmoschus; Animals; Flavonoids; Fructose; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperinsulinism; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Phenols; Phosphatidylinositol 3-Kinases; Phosphorylation; Plant Extracts; Rats; Rats, Wistar; Receptor, Insulin; Rosiglitazone; Thiazolidinediones	2010
Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. International journal of cancer, 2010, Feb-01, Volume: 126, Issue:3 Topics: Adenocarcinoma; Adiponectin; Animals; Autophagy; Blood Glucose; Cachexia; Colonic Neoplasms; Crosses, Genetic; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Muscle, Skeletal; Muscular Atrophy; Neoplasm Proteins; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Random Allocation; Rosiglitazone; Thiazolidinediones; Weight Loss	2010
Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:12 Topics: Anilides; Berberine; Blotting, Western; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Cell Survival; Fatty Acids; Fatty Acids, Nonesterified; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle Fibers, Skeletal; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2009
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of lipid research, 2010, Volume: 51, Issue:4 Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors	2010
Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes, 2010, Volume: 59, Issue:1 Topics: Adipose Tissue; Complement Factor B; Complement Factor H; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Omentum; Organ Specificity; Reference Values; Rosiglitazone; Skin; Thiazolidinediones; Weight Loss; White People	2010
Spirulina protects against rosiglitazone induced osteoporosis in insulin resistance rats. Diabetes research and clinical practice, 2010, Volume: 87, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Bone Density; Dexamethasone; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Male; Osteoporosis; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones	2010
Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling. European journal of pharmacology, 2010, Feb-25, Volume: 628, Issue:1-3 Topics: Animals; Aorta; Arteries; Disease Susceptibility; Endothelium, Vascular; Gene Expression Regulation; Hypertension; Insulin; Insulin Resistance; Male; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vasodilation	2010
Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling. Biochemical pharmacology, 2010, May-01, Volume: 79, Issue:9 Topics: 3T3-L1 Cells; Adipocytes; Animals; Dose-Response Relationship, Drug; Endosomes; Gene Expression Regulation; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazolidinediones; Time Factors	2010
Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study. The Physician and sportsmedicine, 2009, Volume: 37, Issue:1 Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides	2009
Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2009, Volume: 60, Issue:4 Topics: Adipose Tissue, White; Animals; Corn Oil; Dietary Fats; Fatty Acids; Fatty Acids, Monounsaturated; Glucose Clamp Technique; Glycogen; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Mice; Muscle, Skeletal; Oleic Acids; Organ Specificity; Random Allocation; Rosiglitazone; Stearoyl-CoA Desaturase; Thiazolidinediones; Up-Regulation	2009
Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:8 Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hyperglycemia; Hypertension; Insulin; Insulin Resistance; Leptin; PPAR gamma; Rats; Rats, Inbred SHR; Rosiglitazone; Telmisartan; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain	2010
Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:1 Topics: Adipose Tissue; Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Metabolic Syndrome; Obesity; Rosiglitazone; Thiazolidinediones; Triglycerides; Waist-Hip Ratio	2010
The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:1 Topics: Adipokines; Adult; Aged; Body Fat Distribution; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; Rosiglitazone; Thiazolidinediones	2010
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3 Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss	2010
Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy. Journal of the American College of Cardiology, 2010, Mar-02, Volume: 55, Issue:9 Topics: Animals; Cardiomyopathies; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardium; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2010
Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. TheScientificWorldJournal, 2010, Feb-19, Volume: 10 Topics: Antidepressive Agents; Blood Glucose; Depression; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Pilot Projects; Rosiglitazone; Thiazolidinediones; Triglycerides	2010
What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:1 Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2011
Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans. The Journal of clinical investigation, 2010, Volume: 120, Issue:5 Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Gene Expression Regulation; Humans; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; PPAR gamma; Proteasome Endopeptidase Complex; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Ubiquitin Thiolesterase	2010
Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice. Diabetologia, 2010, Volume: 53, Issue:7 Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Nonesterified; Female; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; Sex Characteristics; Thiazolidinediones	2010
Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:1 Topics: Animals; Blotting, Northern; Blotting, Western; Cells, Cultured; Chromatin Immunoprecipitation; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Gene Expression Regulation; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasodilator Agents	2010
Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep. Endocrinology, 2010, Volume: 151, Issue:8 Topics: Animals; Drug Evaluation, Preclinical; Estrous Cycle; Female; Fetal Development; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Polycystic Ovary Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Reproduction; Rosiglitazone; Sheep; Testosterone; Thiazolidinediones	2010
Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis, 2010, Volume: 211, Issue:2 Topics: Anti-Inflammatory Agents; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Leukocytes, Mononuclear; Nitric Oxide; Obesity; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Time Factors	2010
Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats. European journal of pharmacology, 2010, Oct-10, Volume: 644, Issue:1-3 Topics: Animals; Cholecystokinin; Gene Expression Regulation; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Polymerase Chain Reaction; Postprandial Period; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Rosiglitazone; Thiazolidinediones	2010
Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9 Topics: Body Mass Index; Cell Respiration; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Pioglitazone; Rosiglitazone; Thiazolidinediones	2010
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. Planta medica, 2011, Volume: 77, Issue:3 Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Insulin; Insulin Resistance; Lipids; Liver; Male; Peroxisome Proliferator-Activated Receptors; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2011
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular diabetology, 2010, Oct-18, Volume: 9 Topics: Abdominal Fat; Animals; Anti-Inflammatory Agents; Antigens, Differentiation; Benzimidazoles; Benzoates; CD3 Complex; Chemokine CXCL12; Chemotaxis; Dietary Fats; Disease Models, Animal; Inflammation; Insulin Resistance; Lymphocyte Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; T-Lymphocytes; Telmisartan; Thiazolidinediones; Time Factors	2010
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects. European journal of pharmacology, 2011, Jan-15, Volume: 650, Issue:2-3 Topics: 3T3-L1 Cells; Adipocytes; Animals; Cells, Cultured; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Phenylpropionates; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Water-Electrolyte Balance	2011
Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance. Chinese medical journal, 2010, Volume: 123, Issue:17 Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; CD36 Antigens; Dietary Fats; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Skeletal; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2010
The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:12 Topics: Adult; Aged; Atherosclerosis; Carotid Artery, Internal; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk; Rosiglitazone; Thiazolidinediones; Ultrasonography	2010
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice. The American journal of Chinese medicine, 2010, Volume: 38, Issue:6 Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofibrate; Glucose; Glucose Clamp Technique; Glucose Intolerance; Insulin; Insulin Resistance; Lipid Metabolism; Lipid Metabolism Disorders; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phytotherapy; Rosiglitazone; Thiazolidinediones; Weight Gain	2010
Rosiglitazone balances insulin-induced exo- and endocytosis in single 3T3-L1 adipocytes. Molecular and cellular endocrinology, 2011, Feb-10, Volume: 333, Issue:1 Topics: 3T3-L1 Cells; Adipocytes; Animals; Endocytosis; Exocytosis; Fluorescent Antibody Technique; Fluorometry; Glucose Transporter Type 4; Insulin; Insulin Resistance; Mice; Microscopy, Confocal; Rosiglitazone; Thiazolidinediones	2011
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacological research, 2011, Volume: 63, Issue:4 Topics: Aging; Animals; Collagen; Corn Oil; Diet; Female; Fish Oils; Heart; Hyperglycemia; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Inflammation; Insulin Resistance; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones; Ultrasonography	2011
Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats. The American journal of Chinese medicine, 2011, Volume: 39, Issue:1 Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Area Under Curve; Blood Glucose; Bupleurum; Coptis; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipid Metabolism; Lipids; Muscle, Skeletal; Phytotherapy; Rats; Rats, Inbred OLETF; Rheum; Rosiglitazone; Scutellaria baicalensis; Thiazolidinediones	2011
The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2011, Volume: 49, Issue:5 Topics: Administration, Oral; Analysis of Variance; Animals; Blood Glucose; Body Composition; Curcumin; Diabetes Mellitus, Type 2; Dietary Fats; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha	2011
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:11 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Weight; Drug Synergism; Eating; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Lipoprotein Lipase; Liver; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Rosiglitazone; Sodium Glutamate; Thiazolidinediones	2010
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nature medicine, 2011, Volume: 17, Issue:5 Topics: Aged; Animals; Brain; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Knockout; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Weight Gain	2011
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. Archives of pharmacal research, 2011, Volume: 34, Issue:4 Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones	2011
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes care, 2011, Volume: 34, Issue:7 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones	2011
Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine, 2011, Volume: 40, Issue:2 Topics: Adult; Body Mass Index; C-Reactive Protein; Cells, Cultured; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Granulosa Cells; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Polycystic Ovary Syndrome; PPAR gamma; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Testosterone; Thiazolidinediones; Up-Regulation	2011
Rosiglitazone increases fatty acid Δ9-desaturation and decreases elongase activity index in human skeletal muscle in vivo. Metabolism: clinical and experimental, 2012, Volume: 61, Issue:1 Topics: Acetyltransferases; Cell Line; Fatty Acid Elongases; Fatty Acids; Fatty Acids, Unsaturated; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; PPAR gamma; RNA, Messenger; Rosiglitazone; Stearates; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones	2012
Effect of silybin on high-fat-induced fatty liver in rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2011, Volume: 44, Issue:7 Topics: Animals; Antioxidants; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Liver; Homeostasis; Hypoglycemic Agents; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Silymarin; Thiazolidinediones	2011
Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochimica et biophysica acta, 2011, Volume: 1811, Issue:12 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Transporter Type 4; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligonucleotides, Antisense; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Transfection	2011
Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes, 2011, Volume: 60, Issue:12 Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Female; Hypoglycemic Agents; Insulin Resistance; Osteoporosis; Rats; Rosiglitazone; Thiazolidinediones	2011
Not only accumulation, but also saturation status of intramuscular lipids is significantly affected by PPARγ activation. Acta physiologica (Oxford, England), 2012, Volume: 205, Issue:1 Topics: Animals; Diet, High-Fat; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Muscle, Skeletal; Physical Conditioning, Animal; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones	2012
Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype. Neonatology, 2012, Volume: 101, Issue:3 Topics: Animals; Animals, Newborn; Biomarkers; Clinical Chemistry Tests; Disease Models, Animal; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Lung; Metabolic Networks and Pathways; Phenotype; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones	2012
Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer biology & therapy, 2011, Dec-01, Volume: 12, Issue:11 Topics: Adipose Tissue; Animals; Anorexia; Blood Glucose; Cachexia; Eating; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Mice; Muscle Strength; Neoplasms; Organ Size; Proteolysis; Rosiglitazone; Thiazolidinediones; Weight Loss	2011
PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology, 2012, Volume: 153, Issue:1 Topics: Animals; Brain; Diet, High-Fat; Hippocampus; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Resistance; Long-Term Synaptic Depression; Male; Mitochondria; Models, Neurological; Neurons; PPAR gamma; Rats; Rats, Wistar; Receptor, Insulin; Rosiglitazone; Thiazolidinediones; Time Factors	2012
Regulation of LYRM1 gene expression by free fatty acids, adipokines, and rosiglitazone in 3T3-L1 adipocytes. Experimental diabetes research, 2012, Volume: 2012 Topics: 3T3-L1 Cells; Adipokines; Animals; Apoptosis Regulatory Proteins; Fatty Acids, Nonesterified; Gene Expression Regulation; Insulin Resistance; Mice; Resistin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2012
The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regulatory peptides, 2012, Feb-10, Volume: 174, Issue:1-3 Topics: Adiponectin; Animals; Body Mass Index; Insulin; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Receptors, Adiponectin; RNA; Rosiglitazone; Thiazolidinediones	2012
Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:5 Topics: Animals; Antidepressive Agents; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Emotions; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Motor Activity; Psychotic Disorders; Rosiglitazone; Swimming; Thiazolidinediones	2012
Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes, 2012, Volume: 61, Issue:4 Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Remodeling	2012
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:4 Topics: Adipokines; Adipose Tissue; Adiposity; Animals; Blood Glucose; Body Composition; Diet, High-Fat; Fatty Liver; Fluorobenzenes; Homeostasis; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Pyrimidines; Resistin; Rosiglitazone; Rosuvastatin Calcium; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Thiazolidinediones; Triglycerides	2012
Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats. Biochimie, 2012, Volume: 94, Issue:8 Topics: Adipose Tissue, Brown; Animals; Fatty Acids; Gene Expression Regulation; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Mitochondria, Heart; Obesity; Pericardium; Phenotype; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2012
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. The Journal of biological chemistry, 2012, Jul-06, Volume: 287, Issue:28 Topics: 3T3-L1 Cells; Animals; Binding, Competitive; Cells, Cultured; Female; Gene Expression; Glycolysis; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Molecular Structure; Obesity; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones	2012
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of psychiatry & neuroscience : JPN, 2012, Volume: 37, Issue:6 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic Agents; Insulin Resistance; Metformin; Olanzapine; Rats; Rosiglitazone; Thiazolidinediones	2012
Insulin sensitization with a peroxisome proliferator-activated receptor γ agonist prevents adrenocortical lipid infiltration and secretory changes induced by a high-sucrose diet. The Journal of endocrinology, 2012, Volume: 214, Issue:3 Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Animals; Corticosterone; Dietary Sucrose; Energy Intake; Hormones; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism Disorders; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Triglycerides	2012
MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model. Journal of ethnopharmacology, 2012, Aug-30, Volume: 143, Issue:1 Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Inbred C57BL; Ophiopogon; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides	2012
[Effects of ursolic acid in ameliorating insulin resistance in liver of KKAy mice via peroxisome proliferator-activated receptors α and γ]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2012, Volume: 10, Issue:7 Topics: Adiponectin; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Liver; Mice; Mice, Inbred C57BL; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triterpenes; Tumor Necrosis Factor-alpha; Ursolic Acid	2012
Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes. Experimental & molecular medicine, 2012, Sep-30, Volume: 44, Issue:9 Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Endoplasmic Reticulum Stress; Insulin Resistance; Mice; Mitochondria; Mitochondrial Turnover; Nitric Oxide Synthase Type II; Nuclear Respiratory Factor 1; Obesity; Palmitic Acid; Rosiglitazone; Thiazolidinediones	2012
Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:1 Topics: Animals; Baroreflex; Diet, High-Fat; Insulin Resistance; Male; Obesity; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2012
Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response. The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:5 Topics: Adipocytes; Adipose Tissue; Animals; Bifidobacterium; Blotting, Western; Diet, Fat-Restricted; Diet, High-Fat; Glycolysis; Hypoglycemic Agents; Inflammation; Insulin Resistance; Intestines; Lactobacillus; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 8; NF-kappa B; Phosphofructokinase-2; Phosphorylation; PPAR gamma; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Toll-Like Receptor 4	2013
Formulation parameters influencing the physicochemical characteristics of rosiglitazone-loaded cationic lipid emulsion. Archives of pharmacal research, 2012, Volume: 35, Issue:7 Topics: Biological Transport; Carcinoma, Hepatocellular; Castor Oil; Cations; Chemistry, Pharmaceutical; Drug Carriers; Drug Stability; Emulsions; Fatty Acids, Monounsaturated; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver Neoplasms; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polysorbates; Quaternary Ammonium Compounds; Rosiglitazone; Solubility; Surface-Active Agents; Technology, Pharmaceutical; Thiazolidinediones	2012
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:6 Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subunit; Fatty Acid-Binding Proteins; Female; Femur; Insulin Resistance; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones	2012
Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin. American journal of physiology. Renal physiology, 2012, Nov-01, Volume: 303, Issue:9 Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Uremia	2012
META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse. Nutrition (Burbank, Los Angeles County, Calif.), 2013, Volume: 29, Issue:1 Topics: Animals; Body Composition; Diet, High-Fat; Dietary Supplements; Glucose Tolerance Test; Humulus; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones	2013
[Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus]. Terapevticheskii arkhiv, 2012, Volume: 84, Issue:8 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2012
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23. BMC medical genetics, 2012, Sep-24, Volume: 13 Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, Human, Pair 10; Diabetes Mellitus, Type 2; Gene Expression Profiling; Genetic Diseases, X-Linked; Genetic Loci; Genetic Predisposition to Disease; Gigantism; Heart Defects, Congenital; Homeodomain Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Insulysin; Intellectual Disability; Kinesins; Linkage Disequilibrium; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone	2012
Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement. AJR. American journal of roentgenology, 2012, Volume: 199, Issue:5 Topics: Adipose Tissue; Adolescent; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy, Familial Partial; Magnetic Resonance Imaging; Rosiglitazone; Thiazolidinediones; Whole Body Imaging	2012
Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia-reperfusion injury in cardio-pulmonary bypass in dogs. Molecular and cellular biochemistry, 2013, Volume: 373, Issue:1-2 Topics: Animals; Blood Glucose; Cardioplegic Solutions; Cardiopulmonary Bypass; Dogs; Gene Expression; Glucose Transporter Type 4; Heart Ventricles; Insulin; Insulin Resistance; Myocardial Reperfusion Injury; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Ventricular Pressure	2013
Effects of rosiglitazone treatment on insulin resistance and TNF-alpha levels in patients with chronic kidney disease: a prospective study. European review for medical and pharmacological sciences, 2012, Volume: 16, Issue:11 Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Humans; Hypoglycemic Agents; Insulin Resistance; Prospective Studies; Renal Insufficiency, Chronic; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2012
Reversal of dexamethasone induced insulin resistance in 3T3L1 adipocytes by 3β-taraxerol of Mangifera indica. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2013, Feb-15, Volume: 20, Issue:3-4 Topics: 3T3-L1 Cells; Adipocytes; Animals; Biomarkers; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Glucose; Glucose Transporter Type 4; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Mangifera; Mice; Oleanolic Acid; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones	2013
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Middle Aged; Nutrition Surveys; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States	2013
In vivo JNK activation in pancreatic β-cells leads to glucose intolerance caused by insulin resistance in pancreas. Diabetes, 2013, Volume: 62, Issue:7 Topics: Animals; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; MAP Kinase Kinase 7; MAP Kinase Signaling System; Mice; Mice, Transgenic; Pancreas; Rosiglitazone; Thiazolidinediones	2013
A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Molecular endocrinology (Baltimore, Md.), 2002, Volume: 16, Issue:11 Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Adipose Tissue, Brown; Aged; Animals; Anti-Obesity Agents; Cell Differentiation; Epididymis; HeLa Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Molecular Structure; Organophosphorus Compounds; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. American journal of physiology. Endocrinology and metabolism, 2003, Volume: 284, Issue:4 Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2003
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes, 2003, Volume: 52, Issue:1 Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2003
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochemical pharmacology, 2003, Jan-15, Volume: 65, Issue:2 Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine	2003
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. Folia biologica, 2002, Volume: 48, Issue:6 Topics: Adipose Tissue; Animals; Disease Models, Animal; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood? European journal of endocrinology, 2003, Volume: 148, Issue:1 Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocorticoids; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. American journal of physiology. Endocrinology and metabolism, 2003, Volume: 284, Issue:3 Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Muscle, Skeletal; Oxazines; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2003
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. The Journal of clinical investigation, 2003, Volume: 111, Issue:5 Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Fatty Liver; Hyperglycemia; Insulin Resistance; Leptin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Leptin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides	2003
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes, 2003, Volume: 52, Issue:4 Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins	2003
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors	2003
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent]. MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10 Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. American journal of physiology. Endocrinology and metabolism, 2003, Volume: 285, Issue:2 Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2003
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes, 2003, Volume: 52, Issue:6 Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Weight; Female; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Mutant Strains; Muscle, Skeletal; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. The Journal of biological chemistry, 2003, Sep-05, Volume: 278, Issue:36 Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Female; Hypoglycemia; Insulin Resistance; Lipid Metabolism; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; RNA; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides	2003
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough]. MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:8 Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diet; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	2003
Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics, 2003, Volume: 3, Issue:8 Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones	2003
Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20, Issue:10 Topics: Adult; Blood Glucose; Diabetes Mellitus, Lipoatrophic; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lamin Type A; Leptin; Mutation; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Skinfold Thickness; Thiazolidinediones; Transcription Factors	2003
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation, 2003, Oct-21, Volume: 108, Issue:16 Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima	2003
Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. European journal of pharmacology, 2003, Sep-12, Volume: 477, Issue:2 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Female; Fluorouracil; Granulocytes; Hematopoietic Stem Cells; Hypoglycemic Agents; Injections, Intraperitoneal; Insulin Resistance; Macrophages; Mice; Neutropenia; Protective Agents; Rosiglitazone; Thiazolidinediones	2003
Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 42, Issue:4 Topics: Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Case-Control Studies; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-6; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones	2003
Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochemical and biophysical research communications, 2003, Nov-14, Volume: 311, Issue:2 Topics: 3T3 Cells; 3T3-L1 Cells; Adipocytes; Animals; Dose-Response Relationship, Drug; Glucose; Insulin Resistance; Interleukin-6; Mice; Proteins; Repressor Proteins; Rosiglitazone; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones; Transcription Factors; Up-Regulation	2003
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy]. MMW Fortschritte der Medizin, 2003, Sep-18, Volume: 145, Issue:38 Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Survival Rate; Thiazolidinediones	2003
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences of the United States of America, 2003, Dec-23, Volume: 100, Issue:26 Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipodystrophy; Liver; Liver Function Tests; Metabolic Syndrome; Mice; Mice, Knockout; Muscle, Skeletal; Organ Specificity; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2003
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Metabolic update: better defining lipodystrophy and treating insulin resistance. AIDS clinical care, 2003, Volume: 15, Issue:9 Topics: Case-Control Studies; Female; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipodystrophy; Male; Rosiglitazone; Thiazolidinediones; Triglycerides	2003
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of clinical investigation, 2003, Volume: 112, Issue:12 Topics: Adipocytes; Adipose Tissue; Animals; Body Weight; Cells, Cultured; Down-Regulation; Gene Expression Regulation; Giant Cells; Immunohistochemistry; In Situ Hybridization; Inflammation; Insulin Resistance; Lymphocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Biological; Neutrophils; Obesity; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Up-Regulation	2003
Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Blood Glucose; Cell Membrane; Colforsin; Dopamine; Heterotrimeric GTP-Binding Proteins; Insulin; Insulin Resistance; Kidney Tubules, Proximal; Male; Obesity; Protein Transport; Rats; Rats, Zucker; Receptors, Dopamine D1; Rosiglitazone; Sodium; Thiazolidinediones; Urine	2004
Effects of insulin-sensitising agents in mice with hepatic insulin resistance. Diabetologia, 2004, Volume: 47, Issue:3 Topics: Animals; Blood Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Metformin; Mice; Mice, Knockout; Mice, Obese; Receptor, Insulin; Rosiglitazone; Thiazolidinediones	2004
[An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too]. MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49 Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Placebos; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors	2003
Increased CD36 protein as a response to defective insulin signaling in macrophages. The Journal of clinical investigation, 2004, Volume: 113, Issue:5 Topics: Animals; Blotting, Northern; Blotting, Western; CD36 Antigens; Chromones; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Foam Cells; Glutathione; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Morpholines; Oxygen; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Tyrosine	2004
Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. The Journal of biological chemistry, 2004, May-07, Volume: 279, Issue:19 Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Biological Transport; Blotting, Western; Body Weight; Cattle; Deoxyglucose; Diabetes Mellitus, Experimental; Glucose; Insulin; Insulin Resistance; Ligands; Ligases; Mice; Muscle, Skeletal; Muscles; Organic Chemicals; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors; Triglycerides; Tyrosine; Ubiquitin-Protein Ligases	2004
Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology, 2004, Volume: 145, Issue:6 Topics: Absorption; Animals; Animals, Genetically Modified; Body Temperature; Diet; Dietary Fats; Disease Susceptibility; Eating; Estradiol; Female; Glucose; Growth Hormone; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Ovariectomy; Phenotype; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Viscera	2004
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thrombosis and haemostasis, 2004, Volume: 91, Issue:4 Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone	2004
Increased adipose tissue expression of Grb14 in several models of insulin resistance. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:9 Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Insulin; Insulin Resistance; Liver; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2004
Rosiglitazone and heart failure: long-term vigilance. Journal of cardiovascular pharmacology and therapeutics, 2004, Volume: 9, Issue:1 Topics: Aged; Diabetes Mellitus; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors	2004
[Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:4 Topics: Animals; Blood Glucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain	2004
Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance. Atherosclerosis, 2004, Volume: 174, Issue:2 Topics: Analysis of Variance; Animals; Blood Glucose; Cricetinae; Dietary Fats; Disease Models, Animal; Glucose Clamp Technique; Hypoglycemic Agents; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Lipoproteins; Male; Mesocricetus; Probability; Random Allocation; Rosiglitazone; Sensitivity and Specificity; Thiazolidinediones	2004
Summaries for patients. Rosiglitazone treatment for fat redistribution and metabolic abnormalities caused by anti-HIV therapy. Annals of internal medicine, 2004, May-18, Volume: 140, Issue:10 Topics: Adiponectin; Adult; Double-Blind Method; Fatty Acids, Nonesterified; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors	2004
Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia, 2004, Volume: 47, Issue:7 Topics: Animals; Blood Proteins; Fatty Acids; Fatty Acids, Nonesterified; Glycerol; Heparin; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides	2004
Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia, 2004, Volume: 47, Issue:9 Topics: Adipocytes; Adipose Tissue, Brown; Animals; Cells, Cultured; Insulin Resistance; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2004
Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:1 Topics: Androgens; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Obesity; Ovary; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones	2005
Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology, 2005, Volume: 146, Issue:1 Topics: Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Carrier Proteins; Cells, Cultured; Cricetinae; Enterocytes; Fasting; Insulin Resistance; Intestinal Mucosa; Intestines; Lipoproteins; Mesocricetus; Polyethylene Glycols; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes, 2004, Volume: 53, Issue:11 Topics: Animals; Cricetinae; Fructose; Hypoglycemic Agents; Insulin Resistance; Lipase; Liver; Male; Mesocricetus; Models, Animal; Rosiglitazone; Thiazolidinediones	2004
Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of disease, 2004, Volume: 17, Issue:3 Topics: Alzheimer Disease; Animals; Blood Glucose; Disease Models, Animal; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Mice, Transgenic; Reference Values; Rosiglitazone; Stress, Physiological; Thiazolidinediones	2004
Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2004, Volume: 24, Issue:5 Topics: Adult; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Ovulation Induction; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones	2004
Revised vs original QUICKI index during diet + rosiglitazone treatment in obese subjects. Diabetes & metabolism, 2004, Volume: 30, Issue:5 Topics: Body Mass Index; Diet, Reducing; Humans; Hypoglycemic Agents; Insulin Resistance; Monitoring, Physiologic; Obesity; Rosiglitazone; Thiazolidinediones; Weight Loss	2004
Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes, 2005, Volume: 54, Issue:2 Topics: Administration, Oral; Animals; Blood Glucose; Coronary Vessels; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Heart; Hypoglycemic Agents; Insulin Resistance; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
Lessons from human mutations in PPARgamma. International journal of obesity (2005), 2005, Volume: 29 Suppl 1 Topics: Adult; Female; Germ-Line Mutation; Humans; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones	2005
S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes, 2005, Volume: 54, Issue:4 Topics: Animals; Glutathione; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred NOD; Muscle, Skeletal; Nitric Oxide; Nitro Compounds; Nitrosation; Obesity; Phosphoproteins; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptor, Insulin; Rosiglitazone; Thiazolidinediones	2005
Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. American journal of physiology. Renal physiology, 2005, Volume: 289, Issue:2 Topics: Animals; beta-Adrenergic Receptor Kinases; Blood Glucose; Blood Pressure; Body Weight; Cell Membrane; Cyclic AMP-Dependent Protein Kinases; G-Protein-Coupled Receptor Kinase 4; GTP-Binding Protein alpha Subunits, Gs; Immunoprecipitation; Insulin; Insulin Resistance; Kidney Tubules, Proximal; Male; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Receptors, Dopamine D1; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones	2005
[Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension]. Sheng li xue bao : [Acta physiologica Sinica], 2005, Apr-25, Volume: 57, Issue:2 Topics: Animals; Aorta; Hypertension; Insulin Resistance; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vasodilation; Vasodilator Agents	2005
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty? Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:5 Topics: Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones	2005
Short-term rosiglitazone treatment in renal transplant recipients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:7 Topics: Cyclosporine; Diabetes Mellitus; Drug Administration Schedule; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin Resistance; Kidney Transplantation; Rosiglitazone; Tacrolimus; Thiazolidinediones	2005
PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: AC133 Antigen; Antigens, CD; Antigens, CD34; Cell Count; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium, Vascular; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycoproteins; Humans; Hyperinsulinism; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Monocytes; Peptides; PPAR gamma; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Triglycerides; Vascular Endothelial Growth Factor A	2005
Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:9 Topics: Adult; C-Reactive Protein; Drug Combinations; Emulsions; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Heparin; Humans; Infusion Pumps; Insulin Resistance; Male; Middle Aged; Obesity; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones; Triglycerides	2005
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. British journal of pharmacology, 2005, Volume: 146, Issue:2 Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Glucose; Glucose Tolerance Test; Glycogen; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Liver Glycogen; Male; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones	2005
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005, Jul-21, Volume: 436, Issue:7049 Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Transporter Type 4; Hepatocytes; Insulin; Insulin Resistance; Liver; Mice; Mice, Knockout; Monosaccharide Transport Proteins; Muscle Proteins; Muscles; Obesity; Oligonucleotide Array Sequence Analysis; Phosphoenolpyruvate Carboxykinase (GTP); Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2005
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. European journal of pharmacology, 2005, Sep-05, Volume: 519, Issue:1-2 Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Metformin; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors	2005
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes, 2005, Volume: 54, Issue:8 Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones	2005
[Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:6 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones	2004
Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. American journal of physiology. Endocrinology and metabolism, 2006, Volume: 290, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypoglycemic Agents; Insulin Resistance; Multienzyme Complexes; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2006
[Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development]. Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 113, Issue:3 Topics: Animals; Blood Glucose; Cholesterol; Dietary Fats; Fatty Liver; Hypercholesterolemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Peptides; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Triglycerides	2005
[Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:2 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2004
[The effect of high fat feeding and rosiglitazone intervention on pancreatic alpha cell in rats]. Zhonghua nei ke za zhi, 2005, Volume: 44, Issue:8 Topics: Animals; Blood Glucose; Cell Proliferation; Dietary Fats; Glucagon-Secreting Cells; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2005
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Nov-03, Volume: 125, Issue:21 Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones	2005
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes, 2005, Volume: 54, Issue:12 Topics: Animals; Blood Glucose; Epididymis; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred Strains; Obesity; Polymerase Chain Reaction; PPAR alpha; PPAR gamma; Pyrimidines; Receptors, Adiponectin; Receptors, Cell Surface; Rosiglitazone; Thiazolidinediones	2005
[Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance]. Zhonghua yi xue za zhi, 2005, Nov-16, Volume: 85, Issue:43 Topics: Adipose Tissue; Animals; Blood Glucose; Dietary Fats; Fatty Acids, Nonesterified; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin Resistance; Male; Phosphoenolpyruvate Carboxykinase (ATP); Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides	2005
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. American journal of physiology. Regulatory, integrative and comparative physiology, 2006, Volume: 290, Issue:1 Topics: Adiponectin; Aged; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Multiprotein Complexes; Rosiglitazone; Thiazolidinediones; Weight Loss	2006
Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:4 Topics: Aged; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Prediabetic State; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Uncoupling Protein 3	2006
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clinical endocrinology, 2006, Volume: 64, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Blood Glucose; Drug Administration Schedule; Female; Glucose Tolerance Test; Humans; Hydrocortisone; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Pituitary ACTH Hypersecretion; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. Journal of endocrinological investigation, 2005, Volume: 28, Issue:11 Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Menstruation; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Thinness	2005
The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes care, 2006, Volume: 29, Issue:3 Topics: Blood Pressure; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Obesity; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio	2006
Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006, Apr-13, Volume: 440, Issue:7086 Topics: 3T3-L1 Cells; Animals; Antioxidants; Body Weight; Catalase; Glucose Tolerance Test; Insulin Resistance; Male; Metalloporphyrins; Mice; Mice, Obese; Obesity; Oxidation-Reduction; Reactive Oxygen Species; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Transgenes	2006
[Dermatomyositis, lipodystrophy and insulin resistance]. Medicina clinica, 2006, Apr-08, Volume: 126, Issue:13 Topics: Child; Dermatomyositis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy; Male; Rosiglitazone; Thiazolidinediones	2006
Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. Acta pharmacologica Sinica, 2006, Volume: 27, Issue:5 Topics: Animals; Arylsulfonates; Blood Glucose; Bone Neoplasms; Cell Line, Tumor; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Mice, Inbred ICR; Molecular Structure; Osteosarcoma; Phenylpropionates; PPAR alpha; PPAR-beta; Pyrimidines; Rosiglitazone; Thiazolidinediones; Triglycerides	2006
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Benzimidazoles; Cell Differentiation; Chlorocebus aethiops; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 3; Gels; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Mice; Obesity; Pioglitazone; Plasmids; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides	2006
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. British journal of pharmacology, 2006, Volume: 148, Issue:5 Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expression; Gluconeogenesis; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Glycogen; Muscles; Obesity; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Propionates; Pyrimidines; Rats; Rats, Wistar; Rosiglitazone; Sodium Glutamate; Thiazolidinediones	2006
Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascular pharmacology, 2006, Volume: 45, Issue:3 Topics: 3T3-L1 Cells; Adipogenesis; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Chlorocebus aethiops; Dose-Response Relationship, Drug; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; PPAR gamma; Promoter Regions, Genetic; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection	2006
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology, 2006, Volume: 147, Issue:9 Topics: 3T3-L1 Cells; Adiponectin; Animals; Blood Glucose; Caspase 3; Caspases; Gene Expression; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle Cells; Muscle Proteins; Muscle, Skeletal; Muscular Atrophy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha; Ubiquitin	2006
[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. Zhonghua yi xue za zhi, 2006, May-16, Volume: 86, Issue:18 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Dietary Fats; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; fas Receptor; Fatty Liver; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha	2006
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:9 Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Obesity; Resistin; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones	2006
Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes, 2006, Volume: 55, Issue:8 Topics: Acetyl-CoA Carboxylase; Acyl Coenzyme A; Adult; AMP-Activated Protein Kinases; Carboxy-Lyases; Diabetes Mellitus, Type 2; Fatty Acid Transport Proteins; Fatty Acids; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Malonyl Coenzyme A; Middle Aged; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; Obesity; Oxidation-Reduction; Protein Serine-Threonine Kinases; Rosiglitazone; Thiazolidinediones; Triglycerides	2006
Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:6 Topics: Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Injections, Subcutaneous; Insulin; Insulin Resistance; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Thiazolidinediones; Uremia; Weight Gain	2006
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes, 2006, Volume: 55, Issue:9 Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus; Gene Expression Regulation; Halofenate; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Mice; Mice, Obese; PPAR gamma; Protein Structure, Tertiary; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Two-Hybrid System Techniques	2006
Insulin sensitization induced by oral cicletanine in conscious rabbits. Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:6 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Blood Vessels; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glucose; Glucose Clamp Technique; Heart Rate; Hypercholesterolemia; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Myocardium; Nitric Oxide; Pyridines; Rabbits; Rosiglitazone; Thiazolidinediones	2006
Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clinical chemistry, 2007, Volume: 53, Issue:1 Topics: Acute-Phase Proteins; Adult; Age Factors; Aged; Animals; Biomarkers; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperglycemia; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Obesity; Oncogene Proteins; Polymerase Chain Reaction; PPAR gamma; Proto-Oncogene Proteins; Rosiglitazone; Sex Factors; Thiazolidinediones	2007
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiological research, 2007, Volume: 56, Issue:6 Topics: Adipose Tissue; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; E-Selectin; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Adhesion Molecule-1; Lipids; Matrix Metalloproteinase 9; Middle Aged; Peroxidase; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1	2007
Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. Diabetologia, 2007, Volume: 50, Issue:1 Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Luciferases, Firefly; Male; Mice; Mice, Inbred Strains; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Transfection	2007
Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes, 2006, Volume: 55, Issue:12 Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Enalapril; Hypertension; Insulin; Insulin Resistance; Rats; Rats, Inbred SHR; Reference Values; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasodilation	2006
Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clinical chemistry, 2007, Volume: 53, Issue:1 Topics: Acute-Phase Proteins; Adipose Tissue; Animals; Body Mass Index; C-Reactive Protein; Humans; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Liver; Mice; Mice, Obese; Obesity; Oncogene Proteins; PPAR gamma; Proto-Oncogene Proteins; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones	2007
Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. European journal of pharmacology, 2007, Apr-30, Volume: 561, Issue:1-3 Topics: Adipocytes; Animals; Blotting, Western; Cell Line; Gene Expression Regulation; Insulin Resistance; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lauric Acids; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; PPAR alpha; PPAR gamma; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2007
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. American journal of physiology. Gastrointestinal and liver physiology, 2007, Volume: 292, Issue:6 Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Apoptosis; Body Weight; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Leptin; Linoleic Acids, Conjugated; Lipid Metabolism; Lipoproteins, VLDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides	2007
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation, 2007, Mar-13, Volume: 115, Issue:10 Topics: Adiponectin; Animals; Apolipoproteins E; Becaplermin; Cell Proliferation; Cells, Cultured; Diet; Disease Models, Animal; Female; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; PPAR gamma; Proto-Oncogene Proteins c-sis; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones	2007
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacological research, 2007, Volume: 55, Issue:5 Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Prediabetic State; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Streptozocin; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents	2007
Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3 Topics: Acyl-CoA Oxidase; Adipocytes, White; Adipose Tissue; Administration, Oral; Animals; Benzimidazoles; Biological Transport; Cell Count; Cell Size; Epididymis; Fatty Acid-Binding Proteins; Gene Expression; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2007
Metabolic syndrome: a work in progress, but a useful construct. Circulation, 2007, Apr-03, Volume: 115, Issue:13 Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes, 2007, Volume: 56, Issue:7 Topics: Animals; Dietary Fats; Disease Models, Animal; Exercise Therapy; Glucose; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2007
[Effects of Shengqi Jiangtang Granule on rat model of insulin resistance and its mechanism]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:5 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Hypoglycemic Agents; Insulin Resistance; Male; Phytotherapy; Protein Kinase C; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2007
Reduced expression of insulin receptors in the kidneys of insulin-resistant rats. Journal of the American Society of Nephrology : JASN, 2007, Volume: 18, Issue:10 Topics: Animals; Gene Expression; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; PPAR gamma; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Angiotensin, Type 1; Receptor, Insulin; Rosiglitazone; Thiazolidinediones	2007
The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo. Pharmacological research, 2007, Volume: 56, Issue:4 Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Blood Glucose; Cell Differentiation; Cell Line, Tumor; Glucose; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; In Vitro Techniques; Indoleacetic Acids; Indoles; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; PPAR alpha; PPAR gamma; Resistin; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones	2007
[Mechanism of rosiglitasone to improve glucose-uptake of 3T3-L1 adipocyte with insulin resistance induced by dexamethasone and insulin]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2007, Volume: 38, Issue:5 Topics: 3T3-L1 Cells; Adipocytes; Animals; Cytoskeletal Proteins; Dexamethasone; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Rosiglitazone; Thiazolidinediones	2007
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2007, Volume: 13, Issue:6 Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid	2007
Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:9 Topics: Animals; Apoptosis; Blood Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Models, Biological; Random Allocation; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2008
Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats. Life sciences, 2007, Nov-10, Volume: 81, Issue:21-22 Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Diet; Electrophoresis, Polyacrylamide Gel; Flavonoids; Flavonols; Fructose; Glucose Transporter Type 4; Glycogen; Hepatocytes; Hypoglycemic Agents; Immunoprecipitation; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphorylation; Rats; Rats, Wistar; Receptor, Insulin; Rosiglitazone; Thiazolidinediones; Triglycerides	2007
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. Journal of pediatric endocrinology & metabolism : JPEM, 2007, Volume: 20, Issue:9 Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Rosiglitazone; Syndrome; Thiazolidinediones	2007
Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. European journal of pharmacology, 2008, Feb-02, Volume: 580, Issue:1-2 Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Animals; Arylsulfonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipids; Mice; Mice, Inbred ICR; Phenylpropionates; Phosphoproteins; PPAR alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2008
[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus]. Orvosi hetilap, 2007, Dec-09, Volume: 148, Issue:49 Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR gamma; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2007
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:49 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats. Journal of hypertension, 2008, Volume: 26, Issue:1 Topics: Administration, Oral; Animals; Arteries; Atropine Derivatives; Autonomic Nervous System; Baroreflex; Blood Glucose; Blood Pressure; Body Weight; Heart Rate; Insulin; Insulin Resistance; Linear Models; Lipids; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Propranolol; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sensitivity and Specificity; Thiazolidinediones; Time Factors	2008
Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat. Naunyn-Schmiedeberg's archives of pharmacology, 2008, Volume: 376, Issue:6 Topics: Action Potentials; Analysis of Variance; Animals; Diabetes Mellitus, Experimental; Electric Stimulation; Heart; Heart Ventricles; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Male; Papillary Muscles; Potassium Channels; Rats; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Ventricular Function	2008
Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:3 Topics: Animals; Energy Intake; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Male; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones	2008
Insulin resistance and impaired functional vasodilation in obese Zucker rats. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:4 Topics: Animals; Antioxidants; Arachidonic Acid; Arterioles; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Disease Models, Animal; Electric Stimulation; Fatty Acids, Unsaturated; Hydrazines; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney Cortex; Male; Muscle, Skeletal; NADPH Oxidases; Obesity; Oxidative Stress; Rats; Rats, Zucker; Receptors, Thromboxane; Rosiglitazone; Spin Labels; Superoxides; Thiazolidinediones; Thromboxanes; Time Factors; Triglycerides; Vasoconstriction; Vasodilation	2008
Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-gamma-initiated signaling. Journal of hypertension, 2008, Volume: 26, Issue:3 Topics: Animals; Disease Models, Animal; Gene Expression; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Myocardial Contraction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; PPAR gamma; Rats; Rats, Inbred WKY; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vasodilator Agents	2008
A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. European journal of pharmacology, 2008, Apr-14, Volume: 584, Issue:1 Topics: 3T3-L1 Cells; Acetates; Adipose Tissue, White; Animals; Cardiomegaly; Cardiovascular Diseases; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Gene Expression Profiling; Gene Expression Regulation; Hemodilution; Humans; Hypoglycemic Agents; Indoles; Insulin Resistance; Male; Mice; Mice, Inbred Strains; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Protein Binding; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Transfection; Water-Electrolyte Balance	2008
Pharmacogenomics of metabolic effects of rosiglitazone. Pharmacogenomics, 2008, Volume: 9, Issue:2 Topics: Adipose Tissue; Adipose Tissue, White; Animals; Cholesterol, Dietary; Diet; Dietary Carbohydrates; Fatty Acids; Gene Expression; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Metabolic Syndrome; Microarray Analysis; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Inbred BN; Rats, Inbred Strains; RNA; Rosiglitazone; Sucrose; Thiazolidinediones	2008
Controversy over the cardiovascular effects of thiazolidinediones. The American journal of medicine, 2008, Volume: 121, Issue:4 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Survival Rate; Thiazolidinediones	2008
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life sciences, 2008, May-07, Volume: 82, Issue:19-20 Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes, 2008, Volume: 57, Issue:8 Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Body Weight; Dietary Fats; Female; Genotype; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Nitric Oxide Synthase Type II; Obesity; Phosphorylation; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones	2008
The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:7 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Rosiglitazone; Thiazolidinediones	2008
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:12 Topics: Adipokines; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult	2008
Treatment options in insulin resistance obesity-related acanthosis nigricans. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:7 Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Octreotide; Retinoids; Rosiglitazone; Thiazolidinediones; Vitamin D	2008
Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocrine journal, 2008, Volume: 55, Issue:4 Topics: Adipocytes; Adipose Tissue, White; Animals; Dietary Fats; Insulin Resistance; Male; Mice; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones	2008
Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1995, Volume: 27, Issue:4 Topics: Adipose Tissue; Animals; Hindlimb; Insulin Resistance; Male; Muscle, Skeletal; Perfusion; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones	1995
A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes, 1994, Volume: 43, Issue:10 Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adipose Tissue, Brown; Animals; Biological Availability; Blood Glucose; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Glycerol; Heart; Hydroxybutyrates; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Liver Glycogen; Male; Muscles; Myocardium; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	1994
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 1997, Mar-27, Volume: 386, Issue:6623 Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection	1997
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes, 1998, Volume: 47, Issue:4 Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; Fatty Acids, Nonesterified; Glycerol; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Mice; Perilipin-1; Phosphoproteins; Prostaglandin D2; Rosiglitazone; Sterol Esterase; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha	1998
Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Molecular pharmacology, 1998, Volume: 53, Issue:6 Topics: 3T3 Cells; Animals; Arthritis, Experimental; Cell Nucleus; Dexamethasone; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Proteins; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiosemicarbazones; Transcription Factors; Triglycerides	1998
Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. The Journal of biological chemistry, 1998, Oct-02, Volume: 273, Issue:40 Topics: Adipocytes; Animals; Biological Transport; Cell Differentiation; CHO Cells; Chromans; Cricetinae; Enzyme Inhibitors; Gene Expression Regulation; Glucose; Insulin; Insulin Resistance; Lipids; Lipoprotein Lipase; Mice; Protein Biosynthesis; Rats; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone	1998
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes, 1999, Volume: 48, Issue:7 Topics: Acetylcholine; Animals; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vascular Resistance; Vasodilator Agents	1999
[Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance]. Medizinische Monatsschrift fur Pharmazeuten, 1999, Volume: 22, Issue:9 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones	1999
Rosiglitazone for type 2 diabetes mellitus. The Medical letter on drugs and therapeutics, 1999, Aug-13, Volume: 41, Issue:1059 Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones	1999
[New antidiabetic in "virtual reality". Eye to eye with insulin resistance]. MMW Fortschritte der Medizin, 2000, May-11, Volume: 142, Issue:19 Topics: Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; User-Computer Interface	2000
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat Diabetes, 2000, Volume: 49, Issue:4 Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3	2000
[Tackling insulin resistance. Control of etiology in type 2 diabetes]. MMW Fortschritte der Medizin, 2000, May-25, Volume: 142, Issue:21 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ (Clinical research ed.), 2000, Jul-29, Volume: 321, Issue:7256 Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2000, Volume: 24, Issue:8 Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors	2000
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. The Journal of clinical investigation, 2000, Volume: 106, Issue:4 Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine	2000
Rosiglitazone. International journal of clinical practice, 2000, Volume: 54, Issue:5 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones; United States	2000
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. MMW Fortschritte der Medizin, 2000, Jul-20, Volume: 142, Issue:28-29 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
[First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated]. MMW Fortschritte der Medizin, 2000, Sep-07, Volume: 142, Issue:36 Topics: Diabetes Mellitus, Type 2; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
[Insulin sensitizer. A new therapy option for type 2 diabetic patients]. MMW Fortschritte der Medizin, 2000, Sep-21, Volume: 142, Issue:38 Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
[New prospects for the type 2 diabetic patient. Delaying disease progression]. MMW Fortschritte der Medizin, 2000, Nov-16, Volume: 142, Issue:46 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early]. MMW Fortschritte der Medizin, 2000, Nov-23, Volume: 142, Issue:47 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2000
The hormone resistin links obesity to diabetes. Nature, 2001, Jan-18, Volume: 409, Issue:6818 Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones	2001
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes, 2001, Volume: 50, Issue:6 Topics: 3T3 Cells; Adipocytes; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Division; Cell Nucleus; DNA-Binding Proteins; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Resistance; Mice; Rosiglitazone; Stem Cells; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution; Transcription Factors	2001
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes, obesity & metabolism, 2001, Volume: 3, Issue:3 Topics: Animals; Body Weight; Carrier Proteins; Eating; Food Deprivation; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondrial Proteins; Neuropeptide Y; Obesity; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3	2001
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. European journal of pharmacology, 2001, Jun-29, Volume: 423, Issue:1 Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2001
[ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?]. MMW Fortschritte der Medizin, 2001, Jul-26, Volume: 143, Issue:30 Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. The Journal of clinical investigation, 2001, Volume: 108, Issue:7 Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors	2001
[Glitazones--a new therapeutic principle in diabetes]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2001, Sep-20, Volume: 121, Issue:22 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular cell, 2001, Volume: 8, Issue:4 Topics: Adipocytes; Amino Acids; Animals; Binding Sites; Blood Glucose; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation; Genes, Reporter; Hypoglycemic Agents; Insulin Resistance; Leucine; Ligands; Male; Mice; Mice, Inbred Strains; Molecular Structure; Protein Binding; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tyrosine	2001
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:11 Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Weight; Glucose; Glucose Clamp Technique; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness	2001
[Infarct prevention for diabetics. To lower blood sugar is not enough]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents	2001
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones]. MMW Fortschritte der Medizin, 2002, Jan-24, Volume: 144, Issue:3-4 Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. Journal of internal medicine, 2001, Volume: 250, Issue:5 Topics: Adolescent; Adult; Apolipoproteins B; Body Mass Index; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mutation; Plasminogen Activator Inhibitor 1; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides	2001
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes, 2002, Volume: 51, Issue:4 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes, 2002, Volume: 51, Issue:4 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors	2002
Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. The Journal of biological chemistry, 2002, Aug-09, Volume: 277, Issue:32 Topics: Animal Nutritional Physiological Phenomena; Animals; Apolipoproteins B; Cricetinae; Fructose; Hepatocytes; Hypoglycemic Agents; Immunoblotting; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipoproteins, VLDL; Liver; Male; Mesocricetus; Microsomes, Liver; Perfusion; Phosphoproteins; Phosphorylation; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides	2002